

Contact

Merck KGaA, Darmstadt, Germany
Investor Relations
Frankfurter Strasse 250
64293 Darmstadt
Germany
Phone: +49 6151 72 3321
e-mail: investor.relations@merckgroup.com
www.merckgroup.com

WKN: 659990
ISIN: DE0006599905
Ticker Symbol: MRK

Financial Statements Q1 2020 – Q4 2021

Content

1 Income statements

- 1.1 Group, quarterly
- 1.2 Life Science, quarterly
- 1.3 Healthcare, quarterly
- 1.4 Electronics, quarterly
- 1.5 Corporate/Others, quarterly
- 1.6 Financial result, quarterly

2 Cash flow statement**3 Balance sheet**

Net sales/Net sales growth by divisions Merck KGaA, Darmstadt, Germany

€ million	2020								2021							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Group	4 369.7	4 119.1	8 488.8	4 447.1	12 935.9	4 598.5	9 045.6	17 534.4	4 630.7	4 870.2	9 500.9	4 972.7	14 473.6	5 213.0	10 185.7	19 686.6
YoY Δ	624.0	147.6	771.6	393.4	1 164.9	217.7	611.1	1 382.7	261.0	751.1	1 012.1	525.6	1 537.7	614.5	1 140.1	2 152.2
Acquisitions Δ	314.7	280.4	595.1	280.1	875.1	-25.9	254.1	849.2	-19.6	-0.5	-20.1	-1.5	-21.6	0.8	-0.7	-20.8
Fx Δ	23.2	-34.9	-11.7	-178.7	-190.4	-237.3	-416.0	-427.7	-251.9	-196.5	-448.4	43.0	-405.5	156.9	199.9	-248.5
Organic Δ	286.1	-97.9	188.2	292.0	480.2	481.0	773.0	961.2	532.5	948.1	1 480.6	484.1	1 964.7	456.8	940.9	2 421.5
Life Science	1 768.9	1 806.2	3 575.1	1 909.9	5 485.0	2 029.9	3 939.7	7 514.9	2 130.6	2 225.1	4 355.7	2 248.5	6 604.1	2 385.9	4 634.4	8 990.0
YoY Δ	107.9	100.8	208.7	194.7	403.3	247.2	441.9	650.5	361.7	418.8	780.5	338.6	1 119.1	356.0	694.6	1 475.1
Acquisitions Δ	0.2	0.4	0.6	0.0	0.7	0.2	0.3	0.9	0.1	0.2	0.3	0.3	0.6	0.8	1.1	1.4
Fx Δ	15.3	-7.4	7.9	-72.4	-64.5	-96.8	-169.3	-161.3	-110.5	-91.0	-201.5	10.9	-190.6	67.0	78.0	-123.6
Organic Δ	92.3	107.8	200.1	267.1	467.2	343.8	610.9	811.0	472.1	509.7	981.8	327.3	1 309.1	288.3	615.6	1 597.4
Healthcare	1 700.5	1 499.2	3 199.7	1 701.5	4 901.2	1 738.0	3 439.5	6 639.2	1 638.9	1 787.7	3 426.7	1 787.6	5 214.2	1 874.6	3 662.2	7 088.9
YoY Δ	219.9	-177.8	42.1	-54.3	-12.2	-62.3	-116.6	-74.5	-61.6	288.5	226.9	86.1	313.0	136.6	222.7	449.6
Acquisitions Δ	0.0	-15.1	-15.1	-20.8	-35.9	-26.2	-47.0	-62.0	-19.7	-0.6	-20.3	-1.8	-22.1	0.0	-1.8	-22.1
Fx Δ	-6.5	-38.0	-44.5	-90.2	-134.7	-109.3	-199.4	-244.0	-100.8	-65.1	-165.9	17.4	-148.4	54.9	72.3	-93.5
Organic Δ	226.4	-124.7	101.7	56.7	158.4	73.1	129.8	231.5	58.9	354.2	413.1	70.4	483.5	81.8	152.2	565.3
Electronics	900.3	813.6	1 713.9	835.7	2 549.6	830.7	1 666.4	3 380.3	861.2	857.4	1 718.5	936.7	2 655.2	952.5	1 889.2	3 607.7
YoY Δ	296.2	224.6	520.8	253.0	773.9	32.8	285.9	806.7	-39.1	43.8	4.6	101.0	105.6	121.8	222.8	227.4
Acquisitions Δ	314.5	295.0	609.5	300.8	910.3	0.0	300.8	910.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fx Δ	14.4	10.6	24.9	-16.1	8.8	-31.2	-47.3	-22.4	-40.6	-40.4	-81.0	14.6	-66.4	35.0	49.6	-31.4
Organic Δ	-32.6	-81.0	-113.6	-31.7	-145.3	64.0	32.4	-81.2	1.5	84.2	85.7	86.3	172.0	86.8	173.1	258.8

Group	2020								2021							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
YoY %	16.7%	3.7%	10.0%	9.7%	9.9%	5.0%	7.2%	8.6%	6.0%	18.2%	11.9%	11.8%	11.9%	13.4%	12.6%	12.3%
Acquisitions %	8.4%	7.1%	7.7%	6.9%	7.4%	-0.6%	3.0%	5.3%	-0.4%	0.0%	-0.2%	0.0%	-0.2%	0.0%	0.0%	-0.1%
Fx %	0.6%	-0.9%	-0.2%	-4.4%	-1.6%	-5.4%	-4.9%	-2.6%	-5.8%	-4.8%	-5.3%	1.0%	-3.1%	3.4%	2.2%	-1.4%
Organic %	7.6%	-2.5%	2.4%	7.2%	4.1%	11.0%	9.2%	6.0%	12.2%	23.0%	17.4%	10.9%	15.2%	9.9%	10.4%	13.8%
Life Science	6.5%	5.9%	6.2%	11.3%	7.9%	13.9%	12.6%	9.5%	20.4%	23.2%	21.8%	17.7%	20.4%	17.5%	17.6%	19.6%
YoY %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Acquisitions %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Fx %	0.9%	-0.4%	0.2%	-4.2%	-1.3%	-5.4%	-4.8%	-2.3%	-6.2%	-5.0%	-5.6%	0.6%	-3.5%	3.3%	2.0%	-1.6%
Organic %	5.6%	6.3%	5.9%	15.6%	9.2%	19.3%	17.5%	11.8%	26.7%	28.2%	27.5%	17.1%	23.9%	14.2%	15.6%	21.3%
Healthcare	14.9%	-10.6%	1.3%	-3.1%	-0.2%	-3.5%	-3.3%	-1.1%	-3.6%	19.2%	7.1%	5.1%	6.4%	7.9%	6.5%	6.8%
YoY %	0.0%	-0.9%	-0.5%	-1.2%	-0.7%	-1.5%	-1.3%	-0.9%	-1.2%	0.0%	-0.6%	-0.1%	-0.5%	0.0%	-0.1%	-0.3%
Acquisitions %	0.0%	-0.9%	-0.5%	-1.2%	-0.7%	-1.5%	-1.3%	-0.9%	-1.2%	0.0%	-0.6%	-0.1%	-0.5%	0.0%	-0.1%	-0.3%
Fx %	-0.4%	-2.3%	-1.4%	-5.1%	-2.7%	-6.1%	-5.6%	-3.6%	-5.9%	-4.3%	-5.2%	1.0%	-3.0%	3.2%	2.1%	-1.4%
Organic %	15.3%	-7.4%	3.2%	3.2%	3.2%	4.1%	3.6%	3.4%	3.5%	23.6%	12.9%	4.1%	9.9%	4.7%	4.4%	8.5%
Electronics	49.0%	38.1%	43.7%	43.4%	43.6%	4.1%	20.7%	31.3%	-4.3%	5.4%	0.3%	12.1%	4.1%	14.7%	13.4%	6.7%
YoY %	52.1%	50.1%	51.1%	51.6%	51.3%	0.0%	21.8%	35.4%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Acquisitions %	52.1%	50.1%	51.1%	51.6%	51.3%	0.0%	21.8%	35.4%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Fx %	2.4%	1.8%	2.1%	-2.8%	0.5%	-3.9%	-3.4%	-0.9%	-4.5%	-5.0%	-4.7%	1.7%	-2.6%	4.2%	3.0%	-0.9%
Organic %	-5.4%	-13.7%	-9.5%	-5.4%	-8.2%	8.0%	2.3%	-3.2%	0.2%	10.3%	5.0%	10.3%	6.7%	10.4%	10.4%	7.7%

EBITDA pre Merck KGaA, Darmstadt, Germany

€ million	2020								2021							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Group	1 181.3	1 074.2	2 255.5	1 700.7	3 956.2	1 245.2	2 945.9	5 201.4	1 510.6	1 576.2	3 086.8	1 551.9	4 638.8	1 464.2	3 016.1	6 102.9
% Margin	27.0%	26.1%	26.6%	38.2%	30.6%	27.1%	32.6%	29.7%	32.6%	32.4%	32.5%	31.2%	32.0%	28.1%	29.6%	31.0%
YoY Δ	252.8	-65.1	187.7	589.4	777.1	39.6	629.0	816.7	329.3	502.0	831.3	-148.8	682.5	219.0	70.2	901.5
Acquisitions Δ	99.6	100.7	200.2	91.5	291.7	-10.6	80.8	281.1	-1.5	-0.7	-2.2	-1.4	-3.6	-1.7	-3.1	-5.3
Fx Δ	18.3	-34.9	-16.6	-86.9	-103.5	-96.0	-183.0	-199.5	-98.6	-55.4	-154.0	38.0	-116.0	83.4	121.5	-32.6
Organic Δ	134.9	-130.9	4.0	584.9	588.9	146.2	731.1	735.1	429.3	558.2	987.5	-185.4	802.1	137.3	-48.1	939.4
Life Science	552.7	569.1	1 121.8	630.2	1 752.0	653.1	1 283.3	2 405.0	793.2	829.0	1 622.2	823.6	2 445.7	840.2	1 663.7	3 285.9
% Margin	31.2%	31.5%	31.4%	33.0%	31.9%	32.2%	32.6%	32.0%	37.2%	37.3%	37.2%	36.6%	37.0%	35.2%	35.9%	36.6%
YoY Δ	37.0	35.8	72.7	99.1	171.8	104.4	203.4	276.2	240.5	259.9	500.4	193.4	693.8	187.1	380.5	880.9
Acquisitions Δ	-2.5	-3.4	-6.0	-4.0	-9.9	-0.6	-4.6	-10.6	-0.5	-0.6	-1.0	-1.2	-2.2	-1.6	-2.7	-3.8
Fx Δ	-2.7	-12.5	-15.3	-30.0	-45.3	-35.1	-65.1	-80.4	-34.6	-21.2	-55.8	10.3	-45.6	22.8	33.1	-22.7
Organic Δ	42.2	51.8	94.0	133.1	227.1	140.1	273.2	367.2	275.6	281.7	557.3	184.3	741.6	165.8	350.1	907.4
Healthcare	472.1	374.0	846.2	896.0	1 742.1	525.1	1 421.1	2 267.3	532.9	581.0	1 113.9	540.8	1 654.7	498.4	1 039.2	2 153.1
% Margin	27.8%	24.9%	26.4%	52.7%	35.5%	30.2%	41.3%	34.1%	32.5%	32.5%	32.5%	30.3%	31.7%	26.6%	28.4%	30.4%
YoY Δ	140.1	-153.8	-13.7	395.2	381.6	-36.0	359.2	345.6	60.8	206.9	267.7	-355.2	-87.5	-26.7	-381.9	-114.1
Acquisitions Δ	0.0	4.9	4.9	1.3	6.2	-7.9	-6.6	-1.7	-1.4	-0.2	-1.5	-0.2	-1.7	-0.2	-0.4	-1.9
Fx Δ	4.4	-21.9	-17.5	-75.1	-92.5	-71.2	-146.2	-163.7	-74.6	-55.6	-130.3	21.1	-109.2	36.2	57.3	-73.0
Organic Δ	135.7	-136.9	-1.1	469.0	467.9	43.0	512.1	510.9	136.8	262.7	399.5	-376.1	23.4	-62.7	-438.8	-39.3
Electronics	285.5	238.3	523.8	254.2	778.0	246.1	500.4	1 024.2	273.8	258.0	531.9	296.8	828.7	299.8	596.6	1 128.4
% Margin	31.7%	29.3%	30.6%	30.4%	30.5%	29.6%	30.0%	30.3%	31.8%	30.1%	30.9%	31.7%	31.2%	31.5%	31.6%	31.3%
YoY Δ	93.0	47.9	140.9	76.8	217.7	3.1	79.9	220.8	-11.7	19.8	8.1	42.6	50.6	53.6	96.2	104.3
Acquisitions Δ	100.3	98.6	198.9	92.6	291.5	0.0	92.6	291.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fx Δ	9.7	5.9	15.6	-10.6	5.0	-15.8	-26.4	-10.8	-18.7	-14.2	-32.9	13.7	-19.2	23.8	37.5	4.6
Organic Δ	-17.0	-56.5	-73.6	-5.2	-78.8	18.9	13.7	-59.9	7.0	34.0	40.9	28.9	69.8	29.8	58.7	99.6
Corporate/Others	-129.1	-107.2	-236.2	-79.7	-315.9	-179.1	-258.8	-495.1	-89.3	-91.8	-181.1	-109.3	-290.4	-174.2	-283.4	-464.5
YoY Δ	-17.3	5.0	-12.3	18.4	6.1	-31.9	-13.6	-25.9	39.7	15.4	55.1	-29.6	25.5	5.0	-24.6	30.5
Acquisitions Δ	1.8	0.6	2.4	1.6	3.9	-2.1	-0.5	1.9								

Income Statement Merck KGaA, Darmstadt, Germany

Group € million	2020								2021								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Net sales	4 369.7	4 119.1	8 488.8	4 447.1	12 935.9	4 598.5	9 045.6	17 534.4	4 630.7	4 870.2	9 500.9	4 972.7	14 473.6	5 213.0	10 185.7	19 686.6	6.0%	18.2%	11.9%	11.8%	11.9%	13.4%	12.6%	12.3%
Cost of sales	-1 653.5	-1 610.3	-3 263.9	-1 776.1	-5 040.0	-1 795.2	-3 571.2	-6 835.1	-1 720.6	-1 813.0	-3 533.5	-1 858.8	-5 392.4	-1 958.8	-3 817.7	-7 351.2	4.1%	12.6%	8.3%	4.7%	7.0%	9.1%	6.9%	7.6%
thereof amortization of intangible assets	-56.7	-57.2	-113.9	-48.4	-162.3	-47.7	-96.1	-209.9	-53.9	-49.0	-102.9	-50.9	-153.8	-47.6	-98.5	-201.5	-4.9%	-14.3%	-9.6%	5.2%	-5.2%	-0.1%	2.6%	-4.0%
Gross profit	2 716.2	2 508.7	5 224.9	2 671.0	7 895.9	2 803.4	5 474.4	10 699.3	2 910.1	3 057.2	5 967.3	3 113.9	9 081.2	3 254.2	6 368.1	12 335.4	7.1%	21.9%	14.2%	16.6%	15.0%	16.1%	16.3%	15.3%
<i>in % of net sales</i>	62.2%	60.9%	61.6%	60.1%	61.0%	61.0%	60.5%	61.0%	62.8%	62.8%	62.8%	62.6%	62.7%	62.4%	62.5%	62.7%								
SG&A	-1 421.0	-1 497.5	-2 918.6	-973.6	-3 892.2	-1 534.3	-2 507.9	-5 426.5	-1 293.0	-1 423.3	-2 716.4	-1 407.0	-4 123.3	-1 625.9	-3 032.8	-5 749.2	-9.0%	-5.0%	-6.9%	44.5%	5.9%	6.0%	20.9%	5.9%
<i>in % of net sales</i>	32.5%	36.4%	34.4%	21.9%	30.1%	33.4%	27.7%	30.9%	27.9%	29.2%	28.6%	28.3%	28.5%	31.2%	29.8%	29.2%								
Marketing and selling expenses	-1 058.7	-1 034.9	-2 093.6	-991.8	-3 085.4	-1 121.8	-2 113.6	-4 207.2	-1 007.3	-1 035.4	-2 042.7	-1 066.3	-3 109.0	-1 194.7	-2 261.0	-4 303.7	-4.9%	0.1%	-2.4%	7.5%	0.8%	6.5%	7.0%	2.3%
thereof amortization of intangible assets (M&S)	-158.8	-165.2	-323.9	-158.5	-482.5	-153.4	-311.9	-635.8	-145.9	-145.7	-291.6	-144.7	-436.4	-152.3	-297.1	-588.7	-8.1%	-11.8%	-10.0%	-8.7%	-9.6%	-0.7%	-4.8%	-7.4%
Administration expenses	-288.5	-298.3	-586.8	-279.7	-866.6	-321.6	-601.3	-1 188.2	-272.9	-307.3	-580.2	-310.1	-890.3	-350.9	-661.0	-1 241.2	-5.4%	3.0%	-1.1%	10.8%	2.7%	9.1%	9.9%	4.5%
Impairment losses and reversals (IFRS 9)	6.0	-4.5	1.5	-1.3	0.1	-5.8	-7.1	-5.7	-6.0	-0.1	-6.0	0.7	-5.3	6.7	7.4	1.4	n.m.	-98.6%	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Other operating expenses/income	-79.8	-159.9	-239.6	299.3	59.7	-85.1	214.2	-25.5	-6.9	-80.5	-87.4	-31.3	-118.7	-87.0	-118.3	-205.7	-91.4%	-49.6%	-63.5%	n.m.	n.m.	2.2%	n.m.	707.9%
Impairments**	-1.9	-111.7	-113.6	-0.7	-114.4	-13.8	-14.6	-128.2	-3.2	-7.8	-11.0	-18.9	-29.9	-22.8	-41.7	-52.7	69.8%	-93.0%	-90.3%	>1.000%	-73.9%	65.4%	186.4%	-58.9%
Research and development	-579.2	-520.0	-1 099.2	-531.0	-1 630.1	-658.0	-1 188.9	-2 288.1	-573.9	-584.5	-1 158.5	-659.5	-1 818.0	-589.6	-1 249.1	-2 407.6	-0.9%	12.4%	5.4%	24.2%	11.5%	-10.4%	5.1%	5.2%
<i>in % of net sales</i>	13.3%	12.6%	12.9%	11.9%	12.6%	14.3%	13.1%	13.0%	12.4%	12.0%	12.2%	13.3%	12.6%	11.3%	12.3%	12.2%								
thereof amortization of intangible assets (R&D)	-2.3	-2.8	-5.1	-2.9	-8.0	-3.7	-6.6	-11.8	-3.0	-4.1	-7.1	-3.3	-10.4	-2.7	-6.0	-13.1	27.9%	46.5%	38.1%	13.6%	29.3%	-27.1%	-9.4%	11.3%
EBIT	715.9	491.2	1 207.1	1 166.5	2 373.6	611.1	1 777.6	2 984.7	1 043.1	1 049.3	2 092.5	1 047.4	3 139.8	1 038.7	2 086.1	4 178.6	45.7%	113.6%	73.3%	-10.2%	32.3%	70.0%	17.4%	40.0%
<i>in % of net sales</i>	16.4%	11.9%	14.2%	26.2%	18.3%	13.3%	19.7%	17.0%	22.5%	21.5%	22.0%	21.1%	21.7%	19.9%	20.5%	21.2%								
Depreciation and amortization	431.6	556.4	987.9	452.9	1 440.9	497.3	950.2	1 938.2	423.7	422.3	846.1	447.4	1 293.5	474.0	921.4	1 767.5	-1.8%	-24.1%	-14.4%	-1.2%	-10.2%	-4.7%	-3.0%	-8.8%
EBITDA	1 147.5	1 047.5	2 195.1	1 619.4	3 814.5	1 108.4	2 727.8	4 922.9	1 466.9	1 471.6	2 938.5	1 494.8	4 433.4	1 512.7	3 007.5	5 946.1	27.8%	40.5%	33.9%	-7.7%	16.2%	36.5%	10.3%	20.8%
<i>in % of net sales</i>	26.3%	25.4%	25.9%	36.4%	29.5%	24.1%	30.2%	28.1%	31.7%	30.2%	30.9%	30.1%	30.6%	29.0%	29.5%	30.2%								
EBITDA pre	1 181.3	1 074.2	2 255.5	1 700.7	3 956.2	1 245.2	2 945.9	5 201.4	1 510.6	1 576.2	3 086.8	1 551.9	4 638.7	1 464.2	3 016.1	6 102.9	27.9%	46.7%	36.9%	-8.7%	17.3%	17.6%	2.4%	17.3%
<i>in % of net sales</i>	27.0%	26.1%	26.6%	38.2%	30.6%	27.1%	32.6%	29.7%	32.6%	32.4%	32.5%	31.2%	32.0%	28.1%	29.6%	31.0%								
Financial result	-98.5	-102.3	-200.7	-101.6	-302.3	-52.0	-153.6	-354.4	-59.1	-94.8	-153.9	-54.2	-208.0	-46.8	-101.0	-254.9	-40.0%	-7.3%	-23.3%	-46.7%	-31.2%	-10.0%	-34.3%	-28.1%
Profit before income tax from continuing operations	617.5	388.9	1 006.4	1 064.9	2 071.3	559.0	1 623.9	2 630.3	984.1	954.6	1 938.6	993.2	2 931.8	991.9	1 985.1	3 923.7	59.4%	145.4%	92.6%	-6.7%	41.5%	77.4%	22.2%	49.2%
Income tax	-159.4	-99.9	-259.4	-258.5	-517.8	-118.8	-377.2	-636.6	-236.2	-207.8	-443.9	-229.4	-673.3	-185.4	-414.8	-858.7	48.1%	107.9%	71.2%	-11.2%	30.0%	56.1%	9.9%	34.9%
<i>Income tax rate</i>	25.8%	25.7%	25.8%	24.3%	25.0%	21.2%	23.2%	24.2%	24.0%	21.8%	22.9%	23.1%	23.0%	18.7%	20.9%	21.9%								
Profit after tax from continuing operations	458.0	289.0	747.0	806.4	1 553.5	440.3	1 246.7	1 993.7	747.9	746.8	1 494.7	763.8	2 258.5	806.6	1 570.4	3 065.0	63.3%	158.4%	100.1%	-5.3%	45.4%	83.2%	26.0%	53.7%
Profit after tax from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Profit after tax	458.0	289.0	747.0	806.4	1 553.5	440.3	1 246.7	1 993.7	747.9	746.8	1 494.7	763.8	2 258.5	806.6	1 570.4	3 065.0	63.3%	158.4%	100.1%	-5.3%	45.4%	83.2%	26.0%	53.7%
of which: attributable to Merck KGaA shareholders (456.1	289.8	746.0	805.5	1 551.4	435.8	1 241.2	1 987.2	746.6	745.2	1 491.8	760.8	2 252.5	802.1	1 562.9	3 054.7	63.7%	157.1%	100.0%	-5.6%	45.2%	84.1%	25.9%	53.7%
of which: attributable to non-controlling interests	1.9	-0.8	1.1	1.0	2.1	4.5	5.4	6.5	1.3	1.6	2.9	3.0	5.9	4.4	7.5	10.4	-31.3%	n.m.	164.4%	214.8%	187.9%	-1.1%	37.1%	58.5%
EPS in €	1.05	0.67	1.72	1.85	3.57	1.00	2.85	4.57	1.72	1.71	3.43	1.75	5.18	1.84	3.59	7.03	63.8%	155.2%	99.4%	-5.4%	45.1%	84.0%	26.0%	53.8%
thereof from continuing operations	1.05	0.67	1.72	1.85	3.57	1.00	2.85	4.57	1.72	1.71	3.43	1.75	5.18	1.84	3.59	7.03	63.8%	155.2%	99.4%	-5.4%	45.1%	84.0%	26.0%	53.8%
thereof from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
EPS pre in €* 	1.50	1.30	2.80	2.34	5.14	1.57	3.91	6.70	2.18	2.24	4.42	2.24	6.66	2.06	4.30	8.72	45.3%	72.3%	57.9%	-4.3%	29.6%	31.2%	10.0%	30.1%
Number of theoretical shares in million	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8								
Reconciliation to EBITDA pre																								
EBITDA	1 147.5	1 047.5	2 195.1	1 619.4	3 814.5	1 108.4	2 727.8	4 922.9	1 466.9	1 471.6	2 938.5	1 494.8	4 433.4	1 512.7	3 007.5	5 946.1	27.8%	40.5%	33.9%	-7.7%	16.2%	36.5%	10.3%	20.8%
Adjustments																								
thereof: Cost of Sales	20.2	2.5	22.7	21.1	43.8	9.1	30.2	52.9	4.4	7.48	11.9	8.8	20.7	4.5	13.3	25.2	-78.2%	197.9%	-47.6%	-58.4%	-52.8%	-50.5%	-56.0%	-52.4%
thereof: Marketing and selling expenses	2.2	10.3	12.5	5.8	18.3	41.6	47.4	59.9	6.4	2.89	9.2	4.0	13.2	3.9	7.9	17.1	188.6%	-71.9%	-26.0%	-31.9%	-27.9%	-90.6%	-83.4%	-71.4%
thereof: Administration expenses	16.4	32.8	49.2	18.2	67.4	31.1	49.3	98.4	20.4	20.07	40.5	29.4	69.9	13.1	42.5	83.0	24.5%	-38.7%	-17.6%	61.6%	3.8%	-57.9%	-13.8%	-15.7%
thereof: Other operating expenses/income	-3.8	-18.6	-22.3	35.3	13.0	27.8	63.1	40.7	10.8	73.08	83.9	14.8	98.7	-75.0	-60.1	23.8	n.m.	n.m.	n.m.	-58.0%	660.4%	n.m.	n.m.	-41.7%
thereof: Research and development	-1.2	-0.3	-1.6	0.8	-0.8	27.3	28.1	26.6	1.7	1.02	2.7	0.1	2.8	5.0	5.1	7.8	n.m.	n.m.	n.m.	-87.3%	n.m.	-81.7%	-81.9%	-70.5%
Total	33.8	26.7	60.5	81.3	141.7	136.8	218.1	278.6	43.7	104.6	148.3	57.1	205.4	-48.5	8.6	156.9	29.4%	292.0%	145.2%	-29.7%	44.9%	n.m.	-96.1%	-43.7%
EBITDA pre	1 181.3	1 074.2	2 255.5	1 700.7	3 956.2	1 245.2	2 945.9	5 201.4	1 510.6	1 576.2	3 086.8	1 551.9	4 638.7	1 464.2	3 016.1	6 102.9	27.9%	46.7%	36.9%	-8.7%	17.3%	17.6%	2.4%	17.3%

Sum of items may not foot due to rounding.

* for continuing operations

** only reflects impairments which classified as adjustments

Reconciliation to EBITDA, EBITDA pre and EPS pre

Group	2020								2021								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
€ million																								
a) Reconciliation to EBITDA and EBITDA pre																								
EBITDA																								
EBIT	715.9	491.2	1 207.1	1 166.5	2 373.6	611.1	1 777.6	2 984.7	1 043.1	1 049.3	2 092.5	1 047.4	3 139.8	1 038.7	2 086.1	4 178.6	45.7%	113.6%	73.3%	-10.2%	32.3%	70.0%	17.4%	40.0%
Depreciation and amortization	431.6	556.4	987.9	452.9	1 440.9	497.3	950.2	1 938.2	423.7	422.3	846.1	447.4	1 293.5	474.0	921.4	1 767.5	-1.8%	-24.1%	-14.4%	-1.2%	-10.2%	-4.7%	-3.0%	-8.8%
Regular depreciation and amortization*	211.9	208.4	420.3	242.3	662.7	235.5	477.8	898.2	217.8	213.5	431.3	229.7	660.9	237.8	467.5	898.8	2.8%	2.4%	2.6%	-5.2%	-0.3%	1.0%	-2.2%	0.1%
Impairments not adjusted	0.0	11.0	11.0	0.0	11.0	43.4	43.4	54.4	0.0	2.1	2.1	0.0	2.1	10.6	10.6	12.7	-100.0%	-80.8%	-80.8%	n.m.	-80.8%	-75.5%	-75.5%	-76.6%
Amortization of purchased intangible assets	217.8	225.2	443.0	209.8	652.8	204.7	414.5	857.4	202.8	198.8	401.6	198.9	600.6	202.7	401.6	803.2	-6.9%	-11.7%	-9.3%	-5.2%	-8.0%	-1.0%	-3.1%	-6.3%
Impairments**	1.9	111.7	113.6	0.7	114.4	13.8	14.6	128.2	3.2	7.8	11.0	18.9	29.9	22.8	41.7	52.7	69.8%	-93.0%	-90.3%	>1.000%	-73.9%	65.4%	186.4%	-58.9%
Total	1 147.5	1 047.5	2 195.1	1 619.4	3 814.5	1 108.4	2 727.8	4 922.9	1 466.9	1 471.6	2 938.5	1 494.8	4 433.4	1 512.7	3 007.5	5 946.1	27.8%	40.5%	33.9%	-7.7%	16.2%	36.5%	10.3%	20.8%
Adjustments																								
Acquisition costs	19.0	-29.5	-10.5	-0.1	-10.6	1.0	1.0	-9.6	-1.0	-16.8	-17.8	0.0	-17.8	0.0	0.0	-17.8	n.m.	-43.2%	69.5%	n.m.	68.0%	-100.0%	-95.2%	86.2%
Restructuring costs	15.4	21.1	36.5	32.7	69.2	92.5	125.2	161.8	27.5	11.6	39.1	22.1	61.2	17.7	39.8	78.9	78.3%	-45.0%	7.0%	-32.5%	-11.6%	-80.9%	-68.2%	-51.2%
Integration costs/IT costs	21.7	37.0	58.8	26.0	84.7	23.2	49.2	107.9	19.3	17.8	37.1	24.5	61.6	19.0	43.5	80.6	-11.0%	-51.9%	-36.8%	-5.7%	-27.3%	-18.2%	-11.6%	-25.3%
Gain (-)/ losses (+) on the divestment of businesses	-30.0	2.1	-27.8	19.4	-8.5	18.2	37.6	9.8	-6.4	88.4	82.1	5.7	87.8	-91.1	-85.4	-3.3	-78.8%	>1.000%	n.m.	-70.6%	n.m.	n.m.	n.m.	n.m.
Other one-time costs	7.6	-4.0	3.5	3.3	6.8	1.9	5.1	8.7	4.3	3.5	7.8	4.8	12.6	5.9	10.7	18.5	-43.6%	n.m.	120.3%	45.6%	84.3%	218.9%	108.4%	113.2%
Total	33.8	26.7	60.5	81.3	141.7	136.8	218.1	278.6	43.73	104.6	148.3	57.1	205.4	-48.5	8.6	156.9	29.4%	292.0%	145.2%	-29.7%	44.9%	n.m.	-96.1%	-43.7%
EBITDA pre	1 181.3	1 074.2	2 255.5	1 700.7	3 956.2	1 245.2	2 945.9	5 201.4	1 510.6	1 576.2	3 086.8	1 551.9	4 638.7	1 464.2	3 016.1	6 102.9	27.9%	46.7%	36.9%	-8.7%	17.3%	17.6%	2.4%	17.3%

b) Reconciliation to EPS pre
1) Reconciliation starting from EBITDA pre

EBITDA pre	1 181.3	1 074.2	2 255.5	1 700.7	3 956.2	1 245.2	2 945.9	5 201.4	1 510.6	1 576.2	3 086.8	1 551.9	4 638.7	1 464.2	3 016.1	6 102.9	27.9%	46.7%	36.9%	-8.7%	17.3%	17.6%	2.4%	17.3%
Regular depreciation and amortization*	-211.9	-208.4	-420.3	-242.3	-662.7	-235.5	-477.8	-898.2	-217.8	-213.5	-431.3	-229.7	-660.9	-237.8	-467.5	-898.8	2.8%	2.4%	2.6%	-5.2%	-0.3%	1.0%	-2.2%	0.1%
Impairments not adjusted	0.0	-11.0	-11.0	0.0	-11.0	-43.4	-43.4	-54.4	0.0	-2.1	-2.1	0.0	-2.1	-10.6	-10.6	-12.7	-100.0%	-80.8%	-80.8%	n.m.	-80.8%	-75.5%	-75.5%	-76.6%
Financial result	-98.5	-102.3	-200.7	-101.6	-302.3	-52.0	-153.6	-354.4	-59.1	-94.8	-153.9	-54.2	-208.0	-46.8	-101.0	-254.9	-40.0%	-7.3%	-23.3%	-46.7%	-31.2%	-10.0%	-34.3%	-28.1%
Adjustments within Financial result	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								
Profit before income tax pre	870.9	752.5	1 623.5	1 356.7	2 980.2	914.3	2 271.1	3 894.5	1 233.8	1 265.8	2 499.6	1 268.1	3 767.6	1 168.9	2 437.0	4 936.6	41.7%	68.2%	54.0%	-6.5%	26.4%	27.8%	7.3%	26.8%
Income tax pre	-217.7	-188.1	-405.9	-339.2	-745.0	-228.6	-567.8	-973.6	-283.8	-291.1	-574.9	-291.7	-866.6	-268.9	-560.5	-1 135.4	30.3%	54.8%	41.6%	-14.0%	16.3%	17.6%	-1.3%	16.6%
underlying tax rate	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%								
Non-controlling interest	-1.9	0.8	-1.1	-1.0	-2.1	-4.5	-5.4	-6.5	-1.3	-1.6	-2.9	-3.0	-5.9	-4.4	-7.5	-10.4	-31.3%	n.m.	164.4%	214.8%	187.9%	-1.1%	37.1%	58.5%
Net income pre	651.3	565.2	1 216.5	1 016.6	2 233.1	681.3	1 697.9	2 914.4	948.7	973.1	1 921.8	973.4	2 895.1	895.7	1 869.1	3 790.8	45.7%	72.2%	58.0%	-4.2%	29.6%	31.5%	10.1%	30.1%
EPS pre in €***	1.50	1.30	2.80	2.34	5.14	1.57	3.91	6.70	2.18	2.24	4.42	2.24	6.66	2.06	4.30	8.72	45.7%	72.2%	58.0%	-4.3%	29.6%	31.5%	10.1%	30.1%

2) Reconciliation starting from Profit before tax

Profit before income tax	617.5	388.9	1 006.4	1 064.9	2 071.3	559.0	1 623.9	2 630.3	984.1	954.6	1 938.6	993.2	2 931.8	991.9	1 985.1	3 923.7	59.4%	145.4%	92.6%	-6.7%	41.5%	77.4%	22.2%	49.2%
Amortization of purchased intangible assets	217.8	225.2	443.0	209.8	652.8	204.7	414.5	857.4	202.8	198.8	401.6	198.9	600.6	202.7	401.6	803.2	-6.9%	-11.7%	-9.3%	-5.2%	-8.0%	-1.0%	-3.1%	-6.3%
Impairments**	1.9	111.7	113.6	0.7	114.4	13.8	14.6	128.2	3.2	7.8	11.0	18.9	29.9	22.8	41.7	52.7	69.8%	-93.0%	-90.3%	>1.000%	-73.9%	65.4%	186.4%	-58.9%
Adjustments																								
Acquisition costs	19.0	-29.5	-10.5	-0.1	-10.6	1.0	1.0	-9.6	-1.0	-16.8	-17.8	0.0	-17.8	0.0	0.0	-17.8	n.m.	-43.2%	69.5%	n.m.	68.0%	-100.0%	-95.2%	86.2%
Restructuring costs	15.4	21.1	36.5	32.7	69.2	92.5	125.2	161.8	27.5	11.6	39.1	22.1	61.2	17.7	39.8	78.9	78.3%	-45.0%	7.0%	-32.5%	-11.6%	-80.9%	-68.2%	-51.2%
Integration costs/IT costs	21.7	37.0	58.8	26.0	84.7	23.2	49.2	107.9	19.3	17.8	37.1	24.5	61.6	19.0	43.5	80.6	-11.0%	-51.9%	-36.8%	-5.7%	-27.3%	-18.2%	-11.6%	-25.3%
Gain (-)/ losses (+) on the divestment of businesses	-30.0	2.1	-27.8	19.4	-8.5	18.2	37.6	9.8	-6.4	88.4	82.1	5.7	87.8	-91.1	-85.4	-3.3	-78.8%	>1.000%	n.m.	-70.6%	n.m.	n.m.	n.m.	n.m.
Other one-time costs	7.6	-4.0	3.5	3.3	6.8	1.9	5.1	8.7	4.3	3.5	7.8	4.8	12.6	5.9	10.7	18.5	-43.6%	n.m.	120.3%	45.6%	84.3%	218.9%	108.4%	113.2%
Adjustments within Financial result	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								
Total adjustments	33.8	26.7	60.5	81.3	141.7	136.8	218.1	278.6	43.7	104.6	148.3	57.1	205.4	-48.5	8.6	156.9	29.4%	292.0%	145.2%	-29.7%	44.9%	n.m.	-96.1%	-43.7%
Profit before income tax pre	870.9	752.5	1 623.5	1 356.7	2 980.2	914.3	2 271.1	3 894.5	1 233.8	1 265.8	2 499.6	1 268.1	3 767.6	1 168.9	2 437.0	4 936.6	41.7%	68.2%	54.0%	-6.5%	26.4%	27.8%	7.3%	26.8%
Income tax pre	-217.7	-188.1	-405.9	-339.2	-745.0	-228.6	-567.8	-973.6	-283.8	-291.1	-574.9	-291.7	-866.6	-268.9	-560.5	-1 135.4	30.3%	54.8%	41.6%	-14.0%	16.3%	17.6%	-1.3%	16.6%
underlying tax rate	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%								
Total costs excluded from Net income	195.2	275.4	470.5	211.1	681.7	245.5	456.6	927.2	202.1	227.9	430.0	212.6	642.6	93.5	306.2	736.1	3.5%	-17.3%	-8.6%	0.7%	-5.7%	-61.9%	-33.0%	-20.6%
Total costs excluded from EPS in €	0.45	0.63	1.08	0.49	1.57	0.56	1.05	2.13	0.46	0.52	0.99	0.49	1.48	0.22	0.70	1.69	2.2%	-17.5%	-8.3%	0.0%	-5.7%	-60.7%	-33.3%	-20.7%
Non-controlling interest	-1.9	0.8	-1.1	-1.0	-2.1	-4.5	-5.4	-6.5	-1.3	-1.6	-2.9	-3.0	-5.9	-4.4	-7.5	-10.4	-31.3%	n.m.	164.4%	214.8%	187.9%	-1.1%	37.1%	58.5%
Net income pre	651.3	565.2	1 216.5	1 016.6	2 233.1	681.3	1 697.9	2 914.4	948.7	973.1	1 921.8	973.4	2 895.1	895.7	1 869.1	3 790.8	45.7%	72.2%	58.0%	-4.2%	29.6%	31.5%	10.1%	30.1%
EPS pre in €***	1.50	1.30	2.80	2.34	5.14	1.57	3.91	6.70	2.18	2.24	4.42	2.24	6.66	2.06	4.30	8.72	45.3%	72.3%	57.9%	-4.3%	29.6%	31.2%	10.0%	30.1%

Number of theoretical shares in million 434.8 434.8 434.8 434.8 434.8 434.8 434.8 434.8 434.8 434.8 434.8 434.8 434.8 434.8 434.8 434.8

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** only reflects impairments which classified as adjustments

*** for continuing operations

Sum of items may not foot due to rounding.

Breakdown of depreciation and amortization and adjustments

Group € million	Division	2020								2021								Change YoY							
		Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
a) Depreciation and amortization																									
Regular depreciation and amortization*	all	211.89	208.4	420.3	242.3	662.7	235.5	477.8	898.2	217.8	213.5	431.3	229.7	660.9	237.8	467.5	898.8	2.8%	2.4%	2.6%	-5.2%	-0.3%	1.0%	-2.2%	0.1%
Impairments not adjusted	all	0.0	11.0	11.0	0.0	11.0	43.4	43.4	54.4	0.0	2.1	2.1	0.0	2.1	10.6	10.6	12.7	-100.0%	-80.8%	-80.8%	n.m.	-80.8%	-75.5%	-75.5%	-76.6%
Amortization of purchased intangible assets																									
Life Science	LS	118.9	119.5	238.4	112.9	351.4	111.5	224.5	462.9	110.3	111.6	221.9	108.1	330.1	111.1	219.2	441.2	-7.2%	-6.6%	-6.9%	-4.3%	-6.1%	-0.4%	-2.3%	-4.7%
Healthcare	HC	10.1	16.0	26.1	12.9	39.0	12.8	25.7	51.8	11.1	7.0	18.2	7.0	25.2	8.2	15.3	33.4	10.0%	-56.0%	-30.5%	-45.6%	-35.5%	-35.6%	-40.6%	-35.5%
Electronics	EL	88.8	89.7	178.4	84.0	262.4	80.3	164.3	342.7	81.4	80.2	161.6	83.8	245.3	83.3	167.1	328.6	-8.3%	-10.6%	-9.5%	-0.3%	-6.5%	3.7%	1.7%	-4.1%
Total		217.8	225.2	443.0	209.8	652.8	204.7	414.5	857.4	202.8	198.8	401.6	198.9	600.6	202.7	401.6	803.2	-6.9%	-11.7%	-9.3%	-5.2%	-8.0%	-1.0%	-3.1%	-6.3%
Impairments**	all	1.9	111.7	113.6	0.7	114.4	13.8	14.6	128.2	3.2	7.8	11.0	18.9	29.9	22.8	41.7	52.7	69.8%	-93.0%	-90.3%	>1.000%	-73.9%	65.4%	186.4%	-58.9%
Total depreciation and amortization		431.6	556.4	987.9	452.9	1 440.9	497.3	950.2	1 938.2	423.7	422.3	846.1	447.4	1 293.5	474.0	921.4	1 767.5	-1.8%	-24.1%	-14.4%	-1.2%	-10.2%	-4.7%	-3.0%	-8.8%
b) Adjustments																									
Acquisition costs		19.0	-29.5	-10.5	-0.1	-10.6	1.0	1.0	-9.6	-1.0	-16.8	-17.8	0.0	-17.8	0.0	0.0	-17.8	n.m.	-43.2%	69.5%	n.m.	68.0%	-100.0%	-95.2%	86.2%
Restructuring costs																									
Life Science	LS	1.7	1.0	2.8	11.4	14.1	1.7	13.1	15.9	7.5	2.4	9.9	9.2	19.0	6.5	15.6	25.5	329.6%	127.1%	254.3%	-19.3%	34.6%	274.7%	19.4%	60.7%
Healthcare	HC	2.0	12.4	14.4	4.7	19.1	75.7	80.4	94.8	7.3	2.2	9.5	0.1	9.6	1.6	1.6	11.1	263.1%	-82.0%	-33.9%	-98.8%	-50.0%	-97.9%	-98.0%	-88.3%
Electronics	EL	7.4	2.5	9.9	17.1	26.9	3.9	21.0	30.8	8.4	1.5	9.9	8.8	18.7	7.6	16.4	26.3	13.7%	-39.7%	0.2%	-48.2%	-30.5%	93.7%	-21.8%	-14.8%
Corporate/Others	CO	4.3	5.2	9.5	-0.5	9.0	11.2	10.7	20.2	4.3	5.5	9.9	4.0	13.9	2.1	6.1	16.0	0.7%	6.1%	3.7%	n.m.	53.5%	-81.3%	-43.1%	-21.1%
Total		15.4	21.1	36.5	32.7	69.2	92.5	125.2	161.8	27.5	11.6	39.1	22.1	61.2	17.7	39.8	78.9	78.3%	-45.0%	7.0%	-32.5%	-11.6%	-80.9%	-68.2%	-51.2%
Integration costs/IT costs																									
Integration Cost	LS/PM/CO	8.0	12.1	20.1	8.8	29.0	12.1	20.9	41.1	4.9	5.4	10.3	11.1	21.3	9.5	20.6	30.8	-39.2%	-55.5%	-49.0%	25.4%	-26.4%	-21.5%	-1.7%	-24.9%
ERP/HR systems	all	13.7	24.9	38.6	17.1	55.7	11.1	28.2	66.8	14.5	12.4	26.9	13.4	40.3	9.5	22.9	49.8	5.4%	-50.2%	-30.4%	-21.7%	-27.7%	-14.7%	-18.9%	-25.5%
Total		21.7	37.0	58.8	26.0	84.7	23.2	49.2	107.9	19.3	17.8	37.1	24.5	61.6	19.0	43.5	80.6	-11.0%	-51.9%	-36.8%	-5.7%	-27.3%	-18.2%	-11.6%	-25.3%
Gain (-)/ losses (+) on the divestment of businesses																									
Costs related to former business activities	CO	1.8	0.7	2.5	19.5	22.0	3.3	22.8	25.3	-6.3	83.1	76.8	-2.1	74.7	-65.6	-67.7	9.1	n.m.	>1.000%	>1.000%	n.m.	240.0%	n.m.	n.m.	-63.9%
Costs related to former business activities	EL	0.1	0.0	0.1	0.6	0.6	0.0	0.6	0.7	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1	-3.5%	-100.0%	-3.6%	-100.0%	-91.5%	-100.0%	-100.0%	-92.1%
Sale of CH, Allergopharma and others	HC	-31.8	1.4	-30.4	-0.7	-31.1	14.9	14.2	-16.2	-0.2	5.3	5.1	7.8	12.9	-25.6	-17.7	-12.7	-99.3%	275.2%	n.m.	n.m.	n.m.	n.m.	n.m.	-21.8%
Costs related to former business activities	LS	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1	n.m.	-87.4%	>1.000%	n.m.	177.8%	-100.0%	n.m.	524.8%
Total		-30.0	2.1	-27.8	19.4	-8.5	18.2	37.6	9.8	-6.4	88.4	82.1	5.7	87.8	-91.1	-85.4	-3.3	-78.8%	>1.000%	n.m.	-70.6%	n.m.	n.m.	n.m.	n.m.
Other one-time costs																									
Others	HC	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
	LS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
	EL	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
	CO	7.6	-4.0	3.5	3.3	6.8	1.9	5.1	8.7	4.3	3.5	7.8	4.8	12.6	5.9	10.7	18.5	-43.6%	n.m.	120.3%	45.6%	84.3%	218.9%	108.3%	113.2%
Total		7.6	-4.0	3.5	3.3	6.8	1.9	5.1	8.7	4.3	3.5	7.8	4.8	12.6	5.9	10.7	18.5	-43.6%	n.m.	120.3%	45.6%	84.3%	218.9%	108.4%	113.2%
Total adjustments		33.8	26.7	60.5	81.3	141.7	136.8	218.1	278.6	43.7	104.6	148.3	57.1	205.4	-48.5	8.6	156.9	29.4%	292.0%	145.2%	-29.7%	44.9%	n.m.	-96.1%	-43.7%

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.

Income Statement Merck KGaA, Darmstadt, Germany
Life Science

€ million

	2020								2021								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Net sales	1 768.9	1 806.2	3 575.1	1 909.9	5 485.0	2 029.9	3 939.7	7 514.9	2 130.6	2 225.1	4 355.7	2 248.5	6 604.1	2 385.9	4 634.4	8 990.0	20.4%	23.2%	21.8%	17.7%	20.4%	17.5%	17.6%	19.6%
Cost of sales	-744.5	-773.7	-1 518.2	-830.4	-2 348.6	-866.7	-1 697.1	-3 215.3	-849.0	-887.1	-1 736.1	-900.4	-2 636.5	-940.5	-1 840.9	-3 577.0	14.0%	14.6%	14.4%	8.4%	12.3%	8.5%	8.5%	11.2%
thereof amortization of intangible assets	-15.0	-15.4	-30.3	-14.1	-44.4	-13.2	-27.2	-57.6	-13.8	-13.9	-27.7	-14.3	-42.0	-11.0	-25.3	-53.0	-7.9%	-9.5%	-8.7%	1.4%	-5.5%	-16.4%	-7.2%	-8.0%
Gross profit	1 024.4	1 032.5	2 056.9	1 079.5	3 136.4	1 163.1	2 242.6	4 299.6	1 281.6	1 338.0	2 619.6	1 348.0	3 967.6	1 445.4	2 793.4	5 413.0	25.1%	29.6%	27.4%	24.9%	26.5%	24.3%	24.6%	25.9%
<i>in % of net sales</i>	57.9%	57.2%	57.5%	56.5%	57.2%	57.3%	56.9%	57.2%	60.2%	60.1%	60.1%	60.0%	60.1%	60.6%	60.3%	60.2%								
SG&A	-603.8	-571.6	-1 175.4	-587.6	-1 762.9	-625.1	-1 212.7	-2 388.0	-613.4	-607.3	-1 220.7	-645.9	-1 866.6	-716.8	-1 362.6	-2 583.4	1.6%	6.3%	3.9%	9.9%	5.9%	14.7%	12.4%	8.2%
<i>in % of net sales</i>	34.1%	31.6%	32.9%	30.8%	32.1%	30.8%	30.8%	31.8%	28.8%	27.3%	28.0%	28.7%	28.3%	30.0%	29.4%	28.7%								
Marketing and selling expenses	-497.5	-488.1	-985.6	-478.3	-1 463.9	-531.2	-1 009.5	-1 995.2	-501.0	-505.3	-1 006.3	-528.7	-1 535.1	-584.0	-1 112.8	-2 119.1	0.7%	3.5%	2.1%	10.5%	4.9%	9.9%	10.2%	6.2%
thereof amortization of intangible assets (M&S)	-104.0	-104.1	-208.1	-98.7	-306.8	-97.3	-196.1	-404.1	-96.2	-96.1	-192.4	-93.1	-285.4	-99.8	-192.9	-385.3	-7.4%	-7.7%	-7.6%	-5.7%	-7.0%	2.6%	-1.6%	-4.7%
Administration expenses	-89.2	-100.3	-189.5	-88.1	-277.6	-76.3	-164.4	-353.9	-81.6	-92.2	-173.9	-93.2	-267.0	-85.4	-178.6	-352.4	-8.5%	-8.0%	-8.2%	5.7%	-3.8%	11.9%	8.6%	-0.4%
Impairment losses and reversals (IFRS 9)	0.4	-0.9	-0.4	-0.6	-1.0	-0.3	-0.9	-1.3	-5.2	-1.3	-6.5	-0.1	-6.6	3.6	3.5	-3.0	n.m.	53.1%	>1.000%	-83.2%	556.0%	n.m.	n.m.	124.6%
Other operating expenses/income	-17.6	17.7	0.1	-20.6	-20.4	-17.2	-37.8	-37.7	-25.6	-8.4	-34.0	-23.9	-57.9	-50.9	-74.8	-108.8	45.5%	n.m.	n.m.	16.1%	183.2%	195.4%	97.9%	188.8%
Impairments**	0.0	0.0	0.0	0.0	0.0	-2.7	-2.7	-2.7	0.0	-0.1	-0.1	0.0	-0.1	-11.0	-11.0	-11.1	n.m.	n.m.	n.m.	n.m.	n.m.	312.5%	312.5%	316.3%
Research and development	-75.3	-75.4	-150.7	-75.2	-225.9	-87.0	-162.2	-312.9	-75.0	-87.0	-162.0	-88.2	-250.2	-100.5	-188.7	-350.7	-0.4%	15.4%	7.5%	17.3%	10.7%	15.5%	16.3%	12.1%
<i>in % of net sales</i>	4.3%	4.2%	4.2%	3.9%	4.1%	4.3%	4.1%	4.2%	3.5%	3.9%	3.7%	3.9%	3.8%	4.2%	4.1%	3.9%								
thereof amortization of intangible assets (R&D)	0.0	0.0	0.0	-0.1	-0.1	-1.0	-1.1	-1.2	-0.3	-1.6	-1.9	-0.8	-2.7	-0.3	-1.0	-2.9	>1.000%	n.m.	>1.000%	498.4%	>1.000%	-74.0%	-8.8%	153.0%
EBIT	345.3	385.6	730.9	416.8	1 147.6	451.0	867.8	1 598.6	593.1	643.7	1 236.8	614.0	1 850.9	628.1	1 242.2	2 479.0	71.8%	66.9%	69.2%	47.3%	61.3%	39.3%	43.1%	55.1%
<i>in % of net sales</i>	19.5%	21.3%	20.4%	21.8%	20.9%	22.2%	22.0%	21.3%	27.8%	28.9%	28.4%	27.3%	28.0%	26.3%	26.8%	27.6%								
Depreciation and amortization	196.0	198.8	394.8	195.0	589.8	198.7	393.7	788.5	186.0	191.3	377.3	191.9	569.3	208.6	400.5	777.9	-5.1%	-3.8%	-4.4%	-1.6%	-3.5%	5.0%	1.7%	-1.4%
EBITDA	541.3	584.4	1 125.7	611.7	1 737.4	649.7	1 261.5	2 387.2	779.1	835.0	1 614.2	806.0	2 420.2	836.7	1 642.7	3 256.9	43.9%	42.9%	43.4%	31.8%	39.3%	28.8%	30.2%	36.4%
<i>in % of net sales</i>	30.6%	32.4%	31.5%	32.0%	31.7%	32.0%	32.0%	31.8%	36.6%	37.5%	37.1%	35.8%	36.6%	35.1%	35.4%	36.2%								
EBITDA pre	552.7	569.1	1 121.8	630.2	1 752.0	653.1	1 283.3	2 405.0	793.2	829.0	1 622.2	823.6	2 445.7	840.2	1 663.7	3 285.9	43.5%	45.7%	44.6%	30.7%	39.6%	28.6%	29.6%	36.6%
<i>in % of net sales</i>	31.2%	31.5%	31.4%	33.0%	31.9%	32.2%	32.6%	32.0%	37.2%	37.3%	37.2%	36.6%	37.0%	35.2%	35.9%	36.6%								
Reconciliation to EBITDA pre																								
EBITDA	541.3	584.4	1 125.7	611.7	1 737.4	649.7	1 261.5	2 387.2	779.1	835.0	1 614.2	806.0	2 420.2	836.7	1 642.7	3 256.9	43.9%	42.9%	43.4%	31.8%	39.3%	28.8%	30.2%	36.4%
Adjustments																								
thereof: Cost of Sales	0.2	0.0	0.3	6.8	7.1	-1.7	5.1	5.3	0.6	0.5	1.0	2.9	3.9	0.5	3.4	4.4	137.7%	>1.000%	270.1%	-57.9%	-44.9%	n.m.	-33.6%	-17.7%
thereof: Marketing and selling expenses	0.1	0.0	0.1	1.7	1.8	1.8	3.6	3.6	0.5	0.5	1.0	2.1	3.2	2.3	4.5	5.5	593.5%	n.m.	>1.000%	21.6%	74.0%	27.3%	24.5%	50.5%
thereof: Administration expenses	9.3	12.1	21.5	7.7	29.1	3.1	10.8	32.3	7.5	8.0	15.5	9.3	24.8	-3.2	6.1	21.5	-19.9%	-34.1%	-27.9%	21.3%	-14.9%	n.m.	-43.8%	-33.2%
thereof: Other operating expenses/income	1.8	-27.5	-25.8	2.3	-23.5	-0.5	1.8	-23.9	5.5	-15.0	-9.6	3.3	-6.2	2.4	5.8	-3.8	211.9%	-45.4%	-62.9%	45.2%	-73.4%	n.m.	216.0%	-84.1%
thereof: Research and development	0.0	0.0	0.0	0.0	0.0	0.6	0.6	0.6	0.0	0.0	0.0	0.0	0.0	1.4	1.4	1.4	n.m.	n.m.	n.m.	n.m.	n.m.	145.7%	145.7%	145.7%
Total	11.4	-15.4	-4.0	18.5	14.5	3.3	21.8	17.9	14.1	-6.1	8.0	17.6	25.6	3.4	21.0	29.0	23.2%	-60.5%	n.m.	-4.8%	76.2%	2.9%	-3.6%	62.5%
EBITDA pre	552.7	569.1	1 121.8	630.2	1 752.0	653.1	1 283.3	2 405.0	793.2	829.0	1 622.2	823.6	2 445.7	840.2	1 663.7	3 285.9	43.5%	45.7%	44.6%	30.7%	39.6%	28.6%	29.6%	36.6%

Sum of items may not foot due to rounding.

Detailed reconciliation - Life Science

€ million	2020								2021								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
EBIT	345.3	385.6	730.9	416.8	1 147.6	451.0	867.8	1 598.6	593.1	643.7	1 236.8	614.0	1 850.9	628.1	1 242.2	2 479.0	71.8%	66.9%	69.2%	47.3%	61.3%	39.3%	43.1%	55.1%
Regular depreciation and amortization*	77.1	79.3	156.4	82.0	238.5	84.5	166.6	323.0	75.7	79.6	155.3	83.8	239.1	86.5	170.4	325.7	-1.8%	0.4%	-0.7%	2.2%	0.3%	2.4%	2.3%	0.8%
Amortization of purchased intangible assets	118.9	119.5	238.4	112.9	351.4	111.5	224.5	462.9	110.3	111.6	221.9	108.1	330.1	111.1	219.2	441.2	-7.2%	-6.6%	-6.9%	-4.3%	-6.1%	-0.4%	-2.3%	-4.7%
Impairments**	0.0	0.0	0.0	0.0	0.0	2.7	2.7	2.7	0.0	0.1	0.1	0.0	0.1	11.0	11.0	11.1	n.m.	n.m.	n.m.	n.m.	n.m.	312.5%	312.5%	316.3%
Total depreciation and amortization	196.0	198.8	394.8	195.0	589.8	198.7	393.7	788.5	186.0	191.3	377.3	191.9	569.3	208.6	400.5	777.9	-5.1%	-3.8%	-4.4%	-1.6%	-3.5%	5.0%	1.7%	-1.4%
EBITDA	541.3	584.4	1 125.7	611.7	1 737.4	649.7	1 261.5	2 387.2	779.1	835.0	1 614.2	806.0	2 420.2	836.7	1 642.7	3 256.9	43.9%	42.9%	43.4%	31.8%	39.3%	28.8%	30.2%	36.4%
Adjustments																								
Acquisition costs	0.0	-30.0	-30.0	-0.1	-30.1	0.0	-0.1	-30.1	-1.1	-16.8	-17.9	0.0	-17.9	0.0	0.0	-17.9	n.m.	-43.9%	-40.1%	n.m.	-40.4%	n.m.	n.m.	-40.5%
Restructuring costs																								
Restructuring costs	1.7	1.0	2.8	11.4	14.1	1.7	13.1	15.9	7.5	2.4	9.9	9.2	19.0	6.5	15.6	25.5	329.6%	127.1%	254.3%	-19.3%	34.6%	274.7%	19.4%	60.7%
Total	1.7	1.0	2.8	11.4	14.1	1.7	13.1	15.9	7.5	2.4	9.9	9.2	19.0	6.5	15.6	25.5	329.6%	127.1%	254.3%	-19.3%	34.6%	274.7%	19.4%	60.7%
Integration costs/IT costs																								
Integration Cost	0.8	1.5	2.3	0.0	2.3	0.9	0.8	3.2	0.3	1.0	1.2	0.2	1.4	0.4	0.6	1.8	-65.2%	-35.5%	-46.3%	n.m.	-37.3%	-57.5%	-33.6%	-42.9%
ERP/HR systems	8.8	12.1	20.9	7.2	28.1	0.8	8.0	28.9	7.2	7.4	14.7	8.2	22.9	-3.4	4.8	19.5	-18.0%	-38.4%	-29.8%	13.7%	-18.6%	n.m.	-39.9%	-32.6%
Total	9.7	13.6	23.2	7.2	30.4	1.6	8.8	32.1	7.5	8.4	15.9	8.4	24.3	-3.0	5.4	21.3	-22.1%	-38.1%	-31.5%	16.8%	-20.0%	n.m.	-39.2%	-33.6%
Gain (-)/ losses (+) on the divestment of businesses																								
Costs related to former business activities	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1	n.m.	-87.4%	>1.000%	n.m.	177.8%	-100.0%	n.m.	524.8%
Total	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1	n.m.	-87.4%	>1.000%	n.m.	177.8%	-100.0%	n.m.	524.8%
Other one-time costs																								
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total adjustments	11.4	-15.4	-4.0	18.5	14.5	3.3	21.8	17.9	14.1	-6.1	8.0	17.6	25.6	3.4	21.0	29.0	23.2%	-60.5%	n.m.	-4.8%	76.2%	2.9%	-3.6%	62.5%
EBITDA pre	552.7	569.1	1 121.8	630.2	1 752.0	653.1	1 283.3	2 405.0	793.2	829.0	1 622.2	823.6	2 445.7	840.2	1 663.7	3 285.9	43.5%	45.7%	44.6%	30.7%	39.6%	28.6%	29.6%	36.6%

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.

Income Statement Merck KGaA, Darmstadt, Germany
Healthcare

€ million

	2020								2021								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Net sales	1 700.5	1 499.2	3 199.7	1 701.5	4 901.2	1 738.0	3 439.5	6 639.2	1 638.9	1 787.7	3 426.7	1 787.6	5 214.2	1 874.6	3 662.2	7 088.9	-3.6%	19.2%	7.1%	5.1%	6.4%	7.9%	6.5%	6.8%
Cost of sales	-393.4	-364.4	-757.9	-427.4	-1 185.3	-428.0	-855.4	-1 613.2	-388.3	-420.2	-808.5	-427.5	-1 236.0	-476.6	-904.1	-1 712.6	-1.3%	15.3%	6.7%	0.0%	4.3%	11.4%	5.7%	6.2%
thereof amortization of intangible assets	-0.8	-0.7	-1.5	-0.7	-2.3	-0.7	-1.5	-3.0	-5.2	-1.1	-6.4	-1.1	-7.5	-1.2	-2.3	-8.7	575.5%	54.6%	320.6%	54.4%	233.2%	58.2%	56.3%	189.9%
Gross profit	1 307.1	1 134.8	2 441.9	1 274.1	3 716.0	1 310.0	2 584.1	5 026.0	1 250.6	1 367.6	2 618.2	1 360.0	3 978.2	1 398.0	2 758.1	5 376.2	-4.3%	20.5%	7.2%	6.7%	7.1%	6.7%	6.7%	7.0%
<i>in % of net sales</i>	76.9%	75.7%	76.3%	74.9%	75.8%	75.4%	75.1%	75.7%	76.3%	76.5%	76.4%	76.1%	76.3%	74.6%	75.3%	75.8%								
SG&A	-467.4	-499.8	-967.2	-88.5	-1 055.7	-526.6	-615.1	-1 582.3	-389.4	-452.0	-841.5	-421.0	-1 262.5	-578.9	-1 000.0	-1 841.4	-16.7%	-9.6%	-13.0%	375.7%	19.6%	9.9%	62.6%	16.4%
<i>in % of net sales</i>	27.5%	33.3%	30.2%	5.2%	21.5%	30.3%	17.9%	23.8%	23.8%	25.3%	24.6%	23.6%	24.2%	30.9%	27.3%	26.0%								
Marketing and selling expenses	-423.4	-409.1	-832.5	-382.4	-1 214.9	-449.3	-831.7	-1 664.2	-370.3	-390.7	-761.1	-386.3	-1 147.4	-452.2	-838.5	-1 599.6	-12.5%	-4.5%	-8.6%	1.0%	-5.6%	0.6%	0.8%	-3.9%
thereof amortization of intangible assets (M&S)	-7.5	-13.7	-21.1	-10.6	-31.7	-10.5	-21.0	-42.2	-4.3	-4.3	-8.6	-4.3	-12.9	-5.5	-9.7	-18.3	-42.6%	-68.6%	-59.4%	-59.5%	-59.4%	-47.8%	-53.6%	-56.5%
Administration expenses	-79.5	-80.6	-160.0	-75.5	-235.5	-84.3	-159.8	-319.9	-72.7	-77.7	-150.5	-78.8	-229.2	-83.9	-162.7	-313.1	-8.5%	-3.5%	-6.0%	4.4%	-2.7%	-0.5%	1.8%	-2.1%
Impairment losses and reversals (IFRS 9)	4.9	-3.3	1.6	-0.6	1.0	-5.3	-5.9	-4.3	-1.7	2.6	0.9	0.5	1.3	3.2	3.6	4.5	n.m.	n.m.	-46.5%	n.m.	34.9%	n.m.	n.m.	n.m.
Other operating expenses/income	30.6	-6.9	23.7	370.0	393.7	12.3	382.3	406.0	55.3	13.9	69.2	43.6	112.7	-46.0	-2.4	66.8	80.9%	n.m.	192.2%	-88.2%	-71.4%	n.m.	n.m.	-83.6%
Impairments**	-1.9	0.0	-1.9	0.0	-1.9	-0.2	-0.2	-2.0	0.0	-2.8	-2.8	-0.1	-2.9	-3.0	-3.1	-6.0	-100.0%	n.m.	51.8%	n.m.	57.1%	>1.000%	>1.000%	192.6%
Research and development	-417.4	-365.7	-783.2	-378.2	-1 161.4	-478.5	-856.8	-1 639.9	-416.4	-414.8	-831.2	-485.8	-1 317.0	-395.1	-881.0	-1 712.2	-0.2%	13.4%	6.1%	28.5%	13.4%	-17.4%	2.8%	4.4%
<i>in % of net sales</i>	24.5%	24.4%	24.5%	22.2%	23.7%	27.5%	24.9%	24.7%	25.4%	23.2%	24.3%	27.2%	25.3%	21.1%	24.1%	24.2%								
thereof amortization of intangible assets (R&D)	-1.9	-1.6	-3.5	-1.6	-5.1	-1.6	-3.2	-6.7	-1.6	-1.6	-3.2	-1.6	-4.8	-1.6	-3.2	-6.4	-14.2%	0.0%	-7.6%	0.0%	-5.2%	0.0%	0.0%	-4.0%
EBIT	422.3	269.2	691.5	807.4	1 498.9	304.9	1 112.3	1 803.8	444.7	500.7	945.5	453.2	1 398.6	424.0	877.1	1 822.6	5.3%	86.0%	36.7%	-43.9%	-6.7%	39.1%	-21.1%	1.0%
<i>in % of net sales</i>	24.8%	18.0%	21.6%	47.5%	30.6%	17.5%	32.3%	27.2%	27.1%	28.0%	27.6%	25.4%	26.8%	22.6%	24.0%	25.7%								
Depreciation and amortization	78.8	89.7	168.5	84.4	252.9	127.8	212.2	380.7	78.4	71.6	150.0	78.5	228.5	94.4	172.9	322.9	-0.5%	-20.2%	-11.0%	-7.0%	-9.6%	-26.1%	-18.5%	-15.2%
EBITDA	501.0	359.0	860.0	891.8	1 751.8	432.7	1 324.5	2 184.5	523.1	572.4	1 095.5	531.7	1 627.2	518.4	1 050.0	2 145.5	4.4%	59.5%	27.4%	-40.4%	-7.1%	19.8%	-20.7%	-1.8%
<i>in % of net sales</i>	29.5%	23.9%	26.9%	52.4%	35.7%	24.9%	38.5%	32.9%	31.9%	32.0%	32.0%	29.7%	31.2%	27.7%	28.7%	30.3%								
EBITDA pre	472.1	374.0	846.2	896.0	1 742.1	525.1	1 421.1	2 267.3	532.9	581.0	1 113.9	540.8	1 654.7	498.4	1 039.2	2 153.1	12.9%	55.3%	31.6%	-39.6%	-5.0%	-5.1%	-26.9%	-5.0%
<i>in % of net sales</i>	27.8%	24.9%	26.4%	52.7%	35.5%	30.2%	41.3%	34.1%	32.5%	32.5%	32.5%	30.3%	31.7%	26.6%	28.4%	30.4%								
Reconciliation to EBITDA pre																								
EBITDA	501.0	359.0	860.0	891.8	1 751.8	432.7	1 324.5	2 184.5	523.1	572.4	1 095.5	531.7	1 627.2	518.4	1 050.0	2 145.5	4.4%	59.5%	27.4%	-40.4%	-7.1%	19.8%	-20.7%	-1.8%
Adjustments																								
thereof: Cost of Sales	0.2	0.0	0.2	0.0	0.2	7.2	7.2	7.4	0.0	-0.4	-0.4	-1.0	-1.4	-1.2	-2.2	-2.6	-100.0%	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
thereof: Marketing and selling expenses	0.8	7.7	8.5	3.9	12.3	35.0	38.9	47.4	5.2	1.7	7.0	0.5	7.4	-0.4	0.0	7.0	536.7%	-77.2%	-18.1%	-87.6%	-39.8%	n.m.	-99.9%	-85.2%
thereof: Administration expenses	1.0	1.7	2.7	0.2	3.0	4.0	4.3	7.0	3.4	1.5	4.9	1.6	6.5	5.1	6.7	11.6	230.9%	-11.2%	80.3%	556.4%	119.3%	26.2%	56.5%	65.8%
thereof: Other operating expenses/income	-30.9	5.7	-25.2	0.1	-25.1	22.0	22.1	-3.1	-0.1	5.2	5.1	8.2	13.3	-26.8	-18.6	-13.6	-99.5%	-9.0%	n.m.	>1.000%	n.m.	n.m.	n.m.	338.2%
thereof: Research and development	0.0	0.0	0.0	0.0	0.0	24.1	24.2	24.2	1.3	0.6	1.9	-0.2	1.7	3.5	3.3	5.1	>1.000%	n.m.	>1.000%	n.m.	>1.000%	-85.7%	-86.4%	-78.7%
Total	-28.9	15.1	-13.8	4.2	-9.6	92.4	96.6	82.8	9.8	8.6	18.4	9.1	27.5	-19.9	-10.8	7.6	n.m.	-43.0%	n.m.	117.6%	n.m.	n.m.	n.m.	-90.8%
EBITDA pre	472.1	374.0	846.2	896.0	1 742.1	525.1	1 421.1	2 267.3	532.9	581.0	1 113.9	540.8	1 654.7	498.4	1 039.2	2 153.1	12.9%	55.3%	31.6%	-39.6%	-5.0%	-5.1%	-26.9%	-5.0%

Sum of items may not foot due to rounding.

Detailed reconciliation - Healthcare

€ million	2020								2021								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
EBIT	422.3	269.2	691.5	807.4	1 498.9	304.9	1 112.3	1 803.8	444.7	500.7	945.5	453.2	1 398.6	424.0	877.1	1 822.6	5.3%	86.0%	36.7%	-43.9%	-6.7%	39.1%	-21.1%	1.0%
Regular depreciation and amortization*	66.8	62.7	129.5	71.5	201.0	71.5	143.0	272.5	67.3	59.6	126.9	71.4	198.3	72.5	143.9	270.8	0.8%	-4.9%	-2.0%	-0.2%	-1.3%	1.4%	0.6%	-0.6%
Impairments not adjusted	0.0	11.0	11.0	0.0	11.0	43.4	43.4	54.4	0.0	2.1	2.1	0.0	2.1	10.6	10.6	12.7	-100.0%	-80.8%	-80.8%	n.m.	-80.8%	-75.5%	-75.5%	-76.6%
Amortization of purchased intangible assets	10.1	16.0	26.1	12.9	39.0	12.8	25.7	51.8	11.1	7.0	18.2	7.0	25.2	8.2	15.3	33.4	10.0%	-56.0%	-30.5%	-45.6%	-35.5%	-35.6%	-40.6%	-35.5%
Impairments**	1.9	0.0	1.9	0.0	1.9	0.2	0.2	2.0	0.0	2.8	2.8	0.1	2.9	3.0	3.1	6.0	-100.0%	n.m.	51.8%	n.m.	57.1%	>1.000%	>1.000%	192.6%
Total depreciation and amortization	78.8	89.7	168.5	84.4	252.9	127.8	212.2	380.7	78.4	71.6	150.0	78.5	228.5	94.4	172.9	322.9	-0.5%	-20.2%	-11.0%	-7.0%	-9.6%	-26.1%	-18.5%	-15.2%
EBITDA	501.0	359.0	860.0	891.8	1 751.8	432.7	1 324.5	2 184.5	523.1	572.4	1 095.5	531.7	1 627.2	518.4	1 050.0	2 145.5	4.4%	59.5%	27.4%	-40.4%	-7.1%	19.8%	-20.7%	-1.8%
Adjustments																								
Acquisition costs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Restructuring costs																								
Restructuring costs	2.0	12.4	14.4	4.7	19.1	75.7	80.4	94.8	7.3	2.2	9.5	0.1	9.6	1.6	1.6	11.1	263.1%	-82.0%	-33.9%	-98.8%	-50.0%	-97.9%	-98.0%	-88.3%
Total	2.0	12.4	14.4	4.7	19.1	75.7	80.4	94.8	7.3	2.2	9.5	0.1	9.6	1.6	1.6	11.1	263.1%	-82.0%	-33.9%	-98.8%	-50.0%	-97.9%	-98.0%	-88.3%
Integration costs/IT costs																								
Integration Cost	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
ERP/HR systems	0.9	1.3	2.2	0.2	2.4	1.9	2.0	4.2	2.7	1.1	3.8	1.3	5.1	4.0	5.3	9.1	196.4%	-16.3%	72.3%	736.5%	114.6%	117.6%	163.9%	115.9%
Total	0.9	1.3	2.2	0.2	2.4	1.9	2.0	4.2	2.7	1.1	3.8	1.3	5.1	4.0	5.3	9.1	196.4%	-16.3%	72.3%	736.5%	114.6%	117.6%	163.9%	115.9%
Gain (-)/ losses (+) on the divestment of businesses																								
Sale of Kuvan and Biosimilars	0.1	-1.7	-1.7	0.0	-1.6	10.6	10.6	9.0	-0.5	5.2	4.7	7.8	12.5	1.1	8.9	13.6	n.m.	n.m.	n.m.	>1.000%	n.m.	-89.4%	-15.9%	52.1%
Sale of Consumer Health	4.6	3.0	7.7	0.9	8.5	1.3	2.2	9.8	0.2	0.1	0.3	0.0	0.4	-26.7	-26.6	-26.3	-95.3%	-95.8%	-95.5%	-97.1%	-95.7%	n.m.	n.m.	n.m.
Sale of Allergopharma	-36.5	0.1	-36.5	-1.8	-38.2	3.8	2.0	-34.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-100.0%	-93.0%	n.m.	-100.0%	n.m.	-100.0%	n.m.	n.m.
Others	0.0	0.0	0.0	0.2	0.2	-0.7	-0.5	-0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%
Total	-31.8	1.4	-30.4	-0.7	-31.1	14.9	14.2	-16.2	-0.2	5.3	5.1	7.8	12.9	-25.6	-17.7	-12.7	-99.3%	275.2%	n.m.	n.m.	n.m.	n.m.	n.m.	-21.8%
Other one-time costs																								
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total adjustments	-28.9	15.1	-13.8	4.2	-9.6	92.4	96.6	82.8	9.8	8.6	18.4	9.1	27.5	-19.9	-10.8	7.6	n.m.	-43.0%	n.m.	117.6%	n.m.	n.m.	n.m.	-90.8%
EBITDA pre	472.1	374.0	846.2	896.0	1 742.1	525.1	1 421.1	2 267.3	532.9	581.0	1 113.9	540.8	1 654.7	498.4	1 039.2	2 153.1	12.9%	55.3%	31.6%	-39.6%	-5.0%	-5.1%	-26.9%	-5.0%

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.

Income Statement Merck KGaA, Darmstadt, Germany
Electronics

€ million

	2020								2021								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Net sales	900.3	813.6	1 713.9	835.7	2 549.6	830.7	1 666.4	3 380.3	861.2	857.4	1 718.5	936.7	2 655.2	952.5	1 889.2	3 607.7	-4.3%	5.4%	0.3%	12.1%	4.1%	14.7%	13.4%	6.7%
Cost of sales	-515.1	-472.0	-987.1	-518.9	-1 506.0	-500.6	-1 019.5	-2 006.6	-483.4	-505.8	-989.2	-530.6	-1 519.8	-540.4	-1 071.1	-2 060.3	-6.1%	7.2%	0.2%	2.3%	0.9%	8.0%	5.1%	2.7%
thereof amortization of intangible assets	-41.0	-41.0	-82.0	-33.6	-115.6	-33.7	-67.3	-149.4	-34.9	-34.0	-68.9	-35.5	-104.4	-35.4	-70.9	-139.8	-14.8%	-17.3%	-16.0%	5.6%	-9.7%	5.0%	5.3%	-6.4%
Gross profit	385.3	341.6	726.8	316.8	1 043.6	330.1	646.9	1 373.7	377.8	351.6	729.3	406.0	1 135.4	412.0	818.1	1 547.4	-1.9%	2.9%	0.3%	28.2%	8.8%	24.8%	26.5%	12.6%
<i>in % of net sales</i>	42.8%	42.0%	42.4%	37.9%	40.9%	39.7%	38.8%	40.6%	43.9%	41.0%	42.4%	43.3%	42.8%	43.3%	43.3%	42.9%								
SG&A	-197.6	-303.4	-501.0	-175.8	-676.8	-182.9	-358.8	-859.8	-185.3	-166.5	-351.8	-209.0	-560.8	-199.8	-408.9	-760.7	-6.2%	-45.1%	-29.8%	18.9%	-17.1%	9.2%	14.0%	-11.5%
<i>in % of net sales</i>	21.9%	37.3%	29.2%	21.0%	26.5%	22.0%	21.5%	25.4%	21.5%	19.4%	20.5%	22.3%	21.1%	21.0%	21.6%	21.1%								
Marketing and selling expenses	-135.6	-133.9	-269.5	-132.7	-402.2	-136.3	-269.0	-538.5	-135.3	-137.1	-272.4	-146.8	-419.1	-154.1	-300.9	-573.2	-0.2%	2.3%	1.0%	10.6%	4.2%	13.1%	11.9%	6.4%
thereof amortization of intangible assets (M&S)	-47.3	-47.4	-94.7	-49.2	-143.9	-45.5	-94.7	-189.4	-45.4	-45.3	-90.6	-47.4	-138.0	-47.0	-94.4	-185.0	-4.1%	-4.5%	-4.3%	-3.8%	-4.1%	3.4%	-0.3%	-2.3%
Administration expenses	-38.4	-44.4	-82.7	-38.4	-121.1	-40.5	-78.9	-161.6	-34.4	-29.6	-64.1	-39.0	-103.1	-34.8	-73.8	-137.9	-10.2%	-33.2%	-22.6%	1.6%	-14.9%	-14.1%	-6.4%	-14.7%
Impairment losses and reversals (IFRS 9)	0.6	-0.7	-0.1	-0.1	-0.2	0.4	0.3	0.1	0.2	-0.4	-0.2	0.2	0.0	-0.9	-0.7	-0.9	-57.3%	-39.6%	45.8%	n.m.	-94.9%	n.m.	n.m.	n.m.
Other operating expenses/income	-24.2	-124.4	-148.6	-4.7	-153.3	-6.5	-11.2	-159.9	-15.8	0.6	-15.2	-23.4	-38.6	-10.1	-33.5	-48.7	-34.8%	n.m.	-89.8%	400.7%	-74.8%	53.8%	198.5%	-69.6%
Impairments**	0.0	-111.6	-111.6	-0.7	-112.3	-11.0	-11.7	-123.3	-2.9	-4.5	-7.4	-18.0	-25.4	-7.6	-25.6	-33.0	n.m.	-96.0%	-93.4%	>1.000%	-77.4%	-30.5%	118.5%	-73.2%
Research and development	-71.3	-68.3	-139.7	-65.5	-205.1	-68.5	-133.9	-273.6	-66.8	-66.7	-133.5	-71.9	-205.4	-72.4	-144.3	-277.8	-6.3%	-2.4%	-4.4%	9.9%	0.1%	5.8%	7.8%	1.6%
<i>in % of net sales</i>	7.9%	8.4%	8.1%	7.8%	8.0%	8.2%	8.0%	8.1%	7.8%	7.8%	7.8%	7.7%	7.7%	7.6%	7.6%	7.7%								
thereof amortization of intangible assets (R&D)	-0.5	-1.2	-1.7	-1.2	-2.8	-1.1	-2.3	-4.0	-1.1	-1.0	-2.0	-0.9	-2.9	-0.9	-1.8	-3.8	136.4%	-21.6%	21.0%	-22.3%	3.3%	-23.3%	-22.8%	-4.3%
EBIT	116.3	-30.2	86.1	75.5	161.6	78.7	154.2	240.3	125.7	118.4	244.0	125.1	369.2	139.8	264.9	508.9	8.1%	n.m.	183.3%	65.8%	128.4%	77.7%	71.8%	111.8%
<i>in % of net sales</i>	12.9%	-3.7%	5.0%	9.0%	6.3%	9.5%	9.3%	7.1%	14.6%	13.8%	14.2%	13.4%	13.9%	14.7%	14.0%	14.1%								
Depreciation and amortization	134.7	249.2	383.9	151.4	535.2	149.2	300.6	684.4	134.2	133.8	268.0	151.5	419.6	141.8	293.4	561.4	-0.3%	-46.3%	-30.2%	0.1%	-21.6%	-4.9%	-2.4%	-18.0%
EBITDA	251.0	219.0	470.0	226.8	696.9	227.9	454.7	924.7	259.9	252.2	512.1	276.7	788.7	281.6	558.3	1 070.4	3.6%	15.1%	9.0%	22.0%	13.2%	23.6%	22.8%	15.7%
<i>in % of net sales</i>	27.9%	26.9%	27.4%	27.1%	27.3%	27.4%	27.3%	27.4%	30.2%	29.4%	29.8%	29.5%	29.7%	29.6%	29.6%	29.7%								
EBITDA pre	285.5	238.3	523.8	254.2	778.0	246.1	500.4	1 024.2	273.8	258.0	531.9	296.8	828.7	299.8	596.6	1 128.4	-4.1%	8.3%	1.5%	16.8%	6.5%	21.8%	19.2%	10.2%
<i>in % of net sales</i>	31.7%	29.3%	30.6%	30.4%	30.5%	29.6%	30.0%	30.3%	31.8%	30.1%	30.9%	31.7%	31.2%	31.5%	31.6%	31.3%								
Reconciliation to EBITDA pre																								
EBITDA	251.0	219.0	470.0	226.8	696.9	227.9	454.7	924.7	259.9	252.2	512.1	276.7	788.7	281.6	558.3	1 070.4	3.6%	15.1%	9.0%	22.0%	13.2%	23.6%	22.8%	15.7%
Adjustments																								
thereof: Cost of Sales	19.8	2.5	22.2	14.4	36.6	3.6	18.0	40.2	3.8	7.4	11.3	6.9	18.2	5.2	12.1	23.4	-80.6%	200.9%	-49.3%	-51.9%	-50.3%	44.2%	-32.6%	-41.9%
thereof: Marketing and selling expenses	1.3	2.6	3.9	0.2	4.2	4.7	4.9	8.9	0.6	0.6	1.3	1.4	2.6	2.0	3.4	4.6	-53.1%	-75.4%	-68.0%	511.1%	-36.9%	-57.5%	-31.8%	-47.8%
thereof: Administration expenses	0.3	8.6	8.9	2.4	11.2	6.2	8.5	17.4	1.7	1.2	2.8	11.0	13.8	1.9	12.8	15.6	437.3%	-86.5%	-68.3%	362.7%	22.5%	-69.8%	50.3%	-10.1%
thereof: Other operating expenses/income	14.4	5.9	20.3	9.6	30.0	1.2	10.8	31.1	7.4	-3.8	3.6	0.6	4.2	8.9	9.6	13.1	-48.9%	n.m.	-82.5%	-93.4%	-86.0%	674.3%	-11.5%	-57.9%
thereof: Research and development	-1.3	-0.3	-1.6	0.8	-0.8	2.6	3.4	1.8	0.4	0.5	0.9	0.3	1.2	0.1	0.4	1.3	n.m.	n.m.	n.m.	-64.7%	n.m.	-94.6%	-87.8%	-28.1%
Total	34.6	19.2	53.8	27.4	81.2	18.3	45.6	99.4	13.9	5.9	19.8	20.1	39.9	18.1	38.3	58.1	-59.7%	-69.5%	-63.2%	-26.4%	-50.8%	-0.7%	-16.1%	-41.6%
EBITDA pre	285.5	238.3	523.8	254.2	778.0	246.1	500.4	1 024.2	273.8	258.0	531.9	296.8	828.7	299.8	596.6	1 128.4	-4.1%	8.3%	1.5%	16.8%	6.5%	21.8%	19.2%	10.2%

Sum of items may not foot due to rounding.

Detailed reconciliation - Electronics

€ million	2020								2021								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
EBIT	116.3	-30.2	86.1	75.5	161.6	78.7	154.2	240.3	125.7	118.4	244.0	125.1	369.2	139.8	264.9	508.9	8.1%	n.m.	183.3%	65.8%	128.4%	77.7%	71.8%	111.8%
Regular depreciation and amortization*	45.9	47.9	93.8	66.6	160.5	57.9	124.5	218.4	50.0	49.1	99.1	49.8	148.9	50.9	100.7	199.8	8.9%	2.5%	5.6%	-25.3%	-7.2%	-12.1%	-19.2%	-8.5%
Amortization of purchased intangible assets	88.8	89.7	178.4	84.0	262.4	80.3	164.3	342.7	81.4	80.2	161.6	83.8	245.3	83.3	167.1	328.6	-8.3%	-10.6%	-9.5%	-0.3%	-6.5%	3.7%	1.7%	-4.1%
Impairments**	0.0	111.6	111.6	0.7	112.3	11.0	11.7	123.3	2.9	4.5	7.4	18.0	25.4	7.6	25.6	33.0	n.m.	-96.0%	-93.4%	>1.000%	-77.4%	-30.5%	118.5%	-73.2%
Total depreciation and amortization	134.7	249.2	383.9	151.4	535.2	149.2	300.6	684.4	134.2	133.8	268.0	151.5	419.6	141.8	293.4	561.4	-0.3%	-46.3%	-30.2%	0.1%	-21.6%	-4.9%	-2.4%	-18.0%
EBITDA	251.0	219.0	470.0	226.8	696.9	227.9	454.7	924.7	259.9	252.2	512.1	276.7	788.7	281.6	558.3	1 070.4	3.6%	15.1%	9.0%	22.0%	13.2%	23.6%	22.8%	15.7%
Adjustments																								
Acquisition costs	19.0	0.5	19.4	0.1	19.5	1.0	1.1	20.5	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1	-99.6%	-94.5%	-99.4%	-50.2%	-99.3%	n.m.	-97.5%	-99.3%
Restructuring costs																								
Restructuring costs	7.4	2.5	9.9	17.1	26.9	3.9	21.0	30.8	8.4	1.5	9.9	8.8	18.7	7.6	16.4	26.3	13.7%	-39.7%	0.2%	-48.2%	-30.5%	93.7%	-21.8%	-14.8%
Total	7.4	2.5	9.9	17.1	26.9	3.9	21.0	30.8	8.4	1.5	9.9	8.8	18.7	7.6	16.4	26.3	13.7%	-39.7%	0.2%	-48.2%	-30.5%	93.7%	-21.8%	-14.8%
Integration costs/IT costs																								
Integration Cost	7.1	10.7	17.8	8.9	26.7	11.2	20.1	37.9	4.6	4.4	9.0	10.9	19.9	9.1	20.0	29.0	-35.7%	-58.5%	-49.4%	22.9%	-25.4%	-18.7%	-0.3%	-23.4%
ERP/HR systems	1.1	5.6	6.6	0.8	7.4	2.1	2.9	9.5	0.9	-0.1	0.7	0.4	1.1	1.4	1.8	2.6	-19.2%	n.m.	-88.8%	-53.2%	-85.0%	-29.9%	-36.5%	-73.1%
Total	8.2	16.3	24.5	9.7	34.1	13.3	22.9	47.4	5.4	4.3	9.8	11.3	21.0	10.6	21.8	31.6	-33.6%	-73.4%	-60.1%	16.6%	-38.4%	-20.4%	-4.8%	-33.4%
Gain (-)/ losses (+) on the divestment of businesses																								
Costs related to former business activities	0.1	0.0	0.1	0.6	0.6	0.0	0.6	0.7	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1	-3.5%	-100.0%	-3.6%	-100.0%	-91.5%	-100.0%	-100.0%	-92.1%
Total	0.1	0.0	0.1	0.6	0.6	0.0	0.6	0.7	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1	-3.5%	-100.0%	-3.6%	-100.0%	-91.5%	-100.0%	-100.0%	-92.1%
Other one-time costs																								
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total adjustments	34.6	19.2	53.8	27.4	81.2	18.3	45.6	99.4	13.9	5.9	19.8	20.1	39.9	18.1	38.3	58.1	-59.7%	-69.5%	-63.2%	-26.4%	-50.8%	-0.7%	-16.1%	-41.6%
EBITDA pre	285.5	238.3	523.8	254.2	778.0	246.1	500.4	1 024.2	273.8	258.0	531.9	296.8	828.7	299.8	596.6	1 128.4	-4.1%	8.3%	1.5%	16.8%	6.5%	21.8%	19.2%	10.2%

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.

Income Statement Merck KGaA, Darmstadt, Germany

Corporate/Others € million	2020								2021								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Net sales	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%
Cost of sales	-0.6	-0.2	-0.8	0.7	-0.1	0.1	0.8	0.1	0.1	0.1	0.2	-0.2	0.0	-1.3	-1.5	-1.3	n.m.	n.m.	n.m.	n.m.	-66.4%	n.m.	n.m.	n.m.
thereof amortization of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Gross profit	-0.6	-0.2	-0.8	0.7	-0.1	0.1	0.8	0.1	0.1	0.1	0.2	-0.2	0.0	-1.3	-1.5	-1.3	n.m.	n.m.	n.m.	n.m.	-66.4%	n.m.	n.m.	n.m.
SG&A	-152.2	-122.8	-275.0	-121.7	-396.7	-199.7	-321.3	-596.3	-104.9	-197.4	-302.3	-131.1	-433.4	-130.3	-261.4	-563.7	-31.1%	60.8%	9.9%	7.7%	9.3%	-34.7%	-18.6%	-5.5%
Marketing and selling expenses	-2.2	-3.8	-6.0	1.6	-4.4	-5.0	-3.4	-9.4	-0.7	-2.3	-3.0	-4.5	-7.4	-4.4	-8.9	-11.8	-68.5%	-39.8%	-50.4%	n.m.	70.1%	-12.4%	161.4%	26.1%
thereof amortization of intangible assets (M&S)	0.0	0.0	0.0	0.0	0.0	-0.1	-0.1	-0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	>1.000%	185.6%	>1.000%	63.9%	>1.000%	-99.3%	-98.6%	-64.4%
Administration expenses	-81.6	-73.0	-154.6	-77.8	-232.4	-120.4	-198.3	-352.8	-84.1	-107.7	-191.8	-99.2	-291.0	-146.8	-245.9	-437.7	3.1%	47.5%	24.1%	27.4%	25.2%	21.9%	24.0%	24.1%
Impairment losses and reversals (IFRS 9)	0.1	0.3	0.4	0.0	0.4	-0.5	-0.5	-0.2	0.7	-0.9	-0.2	0.2	0.0	0.8	1.0	0.8	>1.000%	n.m.	n.m.	n.m.	-96.7%	n.m.	n.m.	n.m.
Other operating expenses/income	-68.5	-46.3	-114.8	-45.5	-160.2	-73.7	-119.2	-234.0	-20.8	-86.6	-107.4	-27.6	-135.0	20.0	-7.7	-115.0	-69.6%	87.0%	-6.5%	-39.2%	-15.8%	n.m.	-93.6%	-50.8%
Impairments**	0.0	-0.2	-0.2	0.0	-0.2	0.0	0.0	-0.2	-0.3	-0.4	-0.7	-0.8	-1.5	-1.2	-2.0	-2.7	n.m.	148.6%	348.7%	n.m.	837.1%	n.m.	n.m.	>1.000%
Research and development	-15.0	-10.6	-25.6	-12.1	-37.7	-24.0	-36.1	-61.7	-15.7	-16.1	-31.8	-13.6	-45.4	-21.5	-35.1	-66.9	4.0%	52.3%	24.0%	12.5%	20.3%	-10.2%	-2.6%	8.4%
thereof amortization of intangible assets (R&D)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
EBIT	-167.9	-133.5	-301.4	-133.1	-434.5	-223.5	-356.6	-658.0	-120.4	-213.5	-333.9	-144.9	-478.8	-153.2	-298.1	-632.0	-28.3%	59.9%	10.8%	8.9%	10.2%	-31.5%	-16.4%	-4.0%
Depreciation and amortization	22.1	18.6	40.8	22.2	63.0	21.5	43.7	84.5	25.1	25.6	50.7	25.5	76.1	29.1	54.5	105.2	13.5%	37.1%	24.3%	14.7%	20.9%	35.0%	24.7%	24.5%
EBITDA	-145.8	-114.8	-260.6	-110.9	-371.5	-202.0	-312.9	-573.5	-95.3	-187.9	-283.2	-119.5	-402.7	-124.1	-243.5	-526.8	-34.6%	63.6%	8.7%	7.7%	8.4%	-38.6%	-22.2%	-8.1%
EBITDA pre	-129.1	-107.2	-236.2	-79.7	-315.9	-179.1	-258.8	-495.1	-89.3	-91.8	-181.1	-109.3	-290.4	-174.2	-283.4	-464.5	-30.8%	-14.4%	-23.3%	37.1%	-8.1%	-2.8%	9.5%	-6.2%
Reconciliation to EBITDA pre																								
EBITDA	-145.8	-114.8	-260.6	-110.9	-371.5	-202.0	-312.9	-573.5	-95.3	-187.9	-283.2	-119.5	-402.7	-124.1	-243.5	-526.8	-34.6%	63.6%	8.7%	7.7%	8.4%	-38.6%	-22.2%	-8.1%
Adjustments																								
thereof: Cost of Sales	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
thereof: Marketing and selling expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	-100.0%	-100.0%	n.m.	>1.000%	>1.000%
thereof: Administration expenses	5.7	10.4	16.1	7.9	24.0	17.8	25.7	41.8	7.9	9.4	17.3	7.5	24.8	9.4	16.9	34.2	37.3%	-9.3%	7.4%	-4.7%	3.4%	-47.3%	-34.2%	-18.2%
thereof: Other operating expenses/income	11.0	-2.7	8.3	23.3	31.6	5.0	28.3	36.6	-1.9	86.7	84.8	2.7	87.5	-59.5	-56.8	28.0	n.m.	n.m.	>1.000%	-88.4%	176.8%	n.m.	n.m.	-23.6%
thereof: Research and development	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	16.7	7.7	24.4	31.2	55.6	22.8	54.0	78.4	6.0	96.1	102.1	10.2	112.3	-50.1	-39.9	62.2	-64.4%	>1.000%	318.1%	-67.2%	101.9%	n.m.	n.m.	-20.7%
EBITDA pre	-129.1	-107.2	-236.2	-79.7	-315.9	-179.1	-258.8	-495.1	-89.3	-91.8	-181.1	-109.3	-290.4	-174.2	-283.4	-464.5	-30.8%	-14.4%	-23.3%	37.1%	-8.1%	-2.8%	9.5%	-6.2%

Sum of items may not foot due to rounding.

Detailed reconciliation - Corporate / Others

€ million	2020								2021								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
EBIT	-167.9	-133.5	-301.4	-133.1	-434.5	-223.5	-356.6	-658.0	-120.4	-213.5	-333.9	-144.9	-478.8	-153.2	-298.1	-632.0	-28.3%	59.9%	10.8%	8.9%	10.2%	-31.5%	-16.4%	-4.0%
Regular depreciation and amortization*	22.1	18.5	40.6	22.2	62.8	21.4	43.6	84.2	24.7	25.2	49.9	24.7	74.6	27.9	52.6	102.5	11.9%	36.1%	22.9%	11.3%	18.8%	30.1%	20.5%	21.7%
Amortization of purchased intangible assets	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	>1.000%	185.6%	>1.000%	63.9%	>1.000%	-99.3%	-98.6%	-64.4%
Impairments**	0.0	0.2	0.2	0.0	0.2	0.0	0.0	0.2	0.3	0.4	0.7	0.8	1.5	1.2	2.0	2.7	n.m.	148.6%	348.7%	n.m.	837.1%	n.m.	n.m.	>1.000%
Total depreciation and amortization	22.1	18.6	40.8	22.2	63.0	21.5	43.7	84.5	25.1	25.6	50.7	25.5	76.1	29.1	54.5	105.2	13.5%	37.1%	24.3%	14.7%	20.9%	35.0%	24.7%	24.5%
EBITDA	-145.8	-114.8	-260.6	-110.9	-371.5	-202.0	-312.9	-573.5	-95.3	-187.9	-283.2	-119.5	-402.7	-124.1	-243.5	-526.8	-34.6%	63.6%	8.7%	7.7%	8.4%	-38.6%	-22.2%	-8.1%
Adjustments																								
Acquisition costs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Restructuring costs																								
Restructuring costs	4.3	5.2	9.5	-0.5	9.0	11.2	10.7	20.2	4.3	5.5	9.9	4.0	13.9	2.1	6.1	16.0	0.7%	6.1%	3.7%	n.m.	53.5%	-81.3%	-43.1%	-21.1%
Total	4.3	5.2	9.5	-0.5	9.0	11.2	10.7	20.2	4.3	5.5	9.9	4.0	13.9	2.1	6.1	16.0	0.7%	6.1%	3.7%	n.m.	53.5%	-81.3%	-43.1%	-21.1%
IT project costs																								
Integration Cost	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								
ERP/HR systems	2.9	5.9	8.9	8.9	17.8	6.4	15.4	24.2	3.7	4.0	7.6	3.6	11.2	7.4	11.0	18.6	24.5%	-32.7%	-13.7%	-60.2%	-37.0%	15.1%	-28.7%	-23.2%
Total	3.0	5.9	8.9	8.9	17.8	6.4	15.4	24.2	3.7	4.0	7.6	3.6	11.2	7.4	11.0	18.6	22.6%	-32.2%	-13.7%	-60.3%	-37.1%	15.0%	-28.7%	-23.3%
Gain (-)/ losses (+) on the divestment of businesses																								
Costs related to former business activities	1.8	0.7	2.5	19.5	22.0	3.3	22.8	25.3	-6.3	83.1	76.8	-2.1	74.7	-65.6	-67.7	9.1	n.m.	>1.000%	>1.000%	n.m.	240.0%	n.m.	n.m.	-63.9%
Total	1.8	0.7	2.5	19.5	22.0	3.3	22.8	25.3	-6.3	83.1	76.8	-2.1	74.7	-65.6	-67.7	9.1	n.m.	>1.000%	>1.000%	n.m.	240.0%	n.m.	n.m.	-63.9%
Other one-time costs																								
Others	7.6	-4.0	3.5	3.3	6.8	1.9	5.1	8.7	4.3	3.5	7.8	4.8	12.6	5.9	10.7	18.5	-43.6%	n.m.	120.3%	45.6%	84.3%	218.9%	108.3%	113.2%
Total	7.6	-4.0	3.5	3.3	6.8	1.9	5.1	8.7	4.3	3.5	7.8	4.8	12.6	5.9	10.7	18.5	-43.6%	n.m.	120.3%	45.6%	84.3%	218.9%	108.3%	113.2%
Total adjustments	16.7	7.7	24.4	31.2	55.6	22.8	54.0	78.4	6.0	96.1	102.1	10.2	112.3	-50.1	-39.9	62.2	-64.4%	>1.000%	318.1%	-67.2%	101.9%	n.m.	n.m.	-20.7%
EBITDA pre	-129.1	-107.2	-236.2	-79.7	-315.9	-179.1	-258.8	-495.1	-89.3	-91.8	-181.1	-109.3	-290.4	-174.2	-283.4	-464.5	-30.8%	-14.4%	-23.3%	37.1%	-8.1%	-2.8%	9.5%	-6.2%

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.

Cash Flow Statement Merck KGaA, Darmstadt, Germany
Group

€ million	2020								2021								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Profit after tax	458.0	289.0	747.1	806.4	1 553.5	440.3	1 246.7	1 993.7	747.9	746.8	1 494.7	763.8	2 258.5	806.6	1 570.4	3 065.0	63.3%	158.4%	100.1%	-5.3%	45.4%	83.2%	26.0%	53.7%
Depreciation/amortization/impairment losses/write-ups	431.5	559.3	990.7	451.5	1 442.2	495.8	947.3	1 938.0	424.0	419.1	843.1	443.5	1 286.6	475.2	918.7	1 761.8	-1.7%	-25.1%	-14.9%	-1.8%	-10.8%	-4.2%	-3.0%	-9.1%
of tangible assets	189.3	208.0	397.3	222.1	619.4	219.3	441.3	838.7	198.1	203.6	401.7	207.6	609.3	231.7	439.3	841.0	4.7%	-2.1%	1.1%	-6.5%	-1.6%	5.7%	-0.5%	0.3%
of intangible assets	242.3	348.3	590.6	230.9	821.5	278.0	508.9	1 099.5	225.6	218.7	444.3	239.8	684.2	242.3	482.1	926.5	-6.9%	-37.2%	-24.8%	3.9%	-16.7%	-12.9%	-5.3%	-15.7%
of financial assets	-0.1	2.9	2.8	-1.4	1.4	-1.5	-3.0	-0.2	0.3	-3.2	-2.9	-3.9	-6.9	1.2	-2.7	-5.6	n.m.	n.m.	n.m.	173.2%	n.m.	n.m.	-9.1%	>1.000%
Changes in working capital	-355.8	-112.4	-468.3	30.9	-437.3	275.0	305.9	-162.3	-88.4	-168.0	-256.4	-81.7	-338.1	-10.5	-92.3	-348.7	-75.2%	49.4%	-45.2%	n.m.	-22.7%	n.m.	n.m.	114.8%
Changes in inventories	-128.7	-117.9	-246.6	51.4	-195.2	110.1	161.5	-85.1	-108.0	-116.7	-224.7	-159.7	-384.4	-87.2	-247.0	-471.6	-16.1%	-1.1%	-8.9%	n.m.	96.9%	n.m.	n.m.	454.4%
Changes in trade accounts receivable	-254.3	74.7	-179.6	-74.6	-254.2	170.3	95.7	-83.9	-314.2	-65.3	-379.5	-53.5	-433.0	122.8	69.3	-310.2	23.6%	n.m.	111.3%	-28.3%	70.3%	-27.9%	-27.6%	269.7%
Changes in trade accounts payable	27.1	-69.2	-42.0	54.1	12.1	-5.5	48.7	6.6	333.8	13.9	347.7	131.5	479.2	-46.1	85.4	433.1	>1.000%	n.m.	n.m.	142.9%	>1.000%	743.6%	75.4%	>1.000%
Changes in provisions	15.8	-53.8	-38.0	-256.2	-294.2	184.7	-71.6	-109.5	-33.7	88.3	54.6	191.4	246.1	-50.1	141.3	196.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Changes in other assets and liabilities	-22.9	-166.5	-189.3	114.0	-75.4	-47.9	66.1	-123.3	160.4	-216.7	-56.3	127.8	71.5	-192.3	-64.6	-120.8	n.m.	30.2%	-70.3%	12.1%	n.m.	301.4%	n.m.	-2.0%
Neutralization of gain/loss on disposal of assets	-34.6	-3.9	-38.4	10.7	-27.7	-70.2	-59.5	-97.9	-5.8	-17.5	-23.3	-8.3	-31.6	7.8	-0.5	-23.8	-83.2%	350.6%	-39.4%	n.m.	14.0%	n.m.	-99.1%	-75.7%
Other non-cash income and expenses	24.4	-9.5	14.9	13.1	28.0	10.6	23.7	38.6	11.6	36.2	47.8	30.2	78.1	8.1	38.4	86.2	-52.3%	n.m.	220.9%	131.3%	179.0%	-23.0%	62.3%	123.6%
Net cash flows from operating activities	516.5	502.2	1 018.7	1 170.4	2 189.1	1 288.1	2 458.6	3 477.2	1 216.1	888.2	2 104.3	1 466.7	3 571.0	1 044.7	2 511.4	4 615.7	135.4%	76.9%	106.6%	25.3%	63.1%	-18.9%	2.2%	32.7%
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Purchase of intangible assets	-17.9	-48.4	-66.3	-34.6	-100.9	-49.4	-84.0	-150.3	-47.1	-21.5	-68.5	-218.5	-287.1	-68.2	-286.8	-355.3	163.4%	-55.7%	3.4%	531.6%	184.5%	38.1%	241.3%	136.4%
Disposal of intangible assets	6.0	7.1	13.1	3.9	17.0	71.4	75.3	88.4	8.7	21.4	30.2	5.2	35.4	3.8	9.0	39.2	44.7%	201.9%	129.7%	33.2%	107.5%	-94.7%	-88.0%	-55.7%
Purchase of property, plant and equipment	-340.8	-200.4	-541.2	-235.4	-776.7	-635.8	-871.3	-1 412.5	-315.0	-253.9	-568.9	-299.1	-868.0	-197.5	-496.6	-1 065.5	-7.6%	26.7%	5.1%	27.0%	11.8%	-68.9%	-43.0%	-24.6%
Disposal of property, plant and equipment	3.5	6.1	9.5	-1.7	7.8	27.3	25.6	35.1	6.4	-1.9	4.5	3.9	8.4	-1.8	2.1	6.6	84.5%	n.m.	-52.9%	n.m.	7.9%	n.m.	-91.9%	-81.3%
Acquisitions	-0.8	-5.8	-6.5	0.0	-6.5	-4.8	-4.8	-11.4	0.0	0.0	0.0	-4.2	-4.2	0.0	-4.2	-4.2	-100.0%	-99.5%	-99.5%	>1.000%	-35.0%	n.m.	-13.4%	-62.8%
Divestments	56.1	-0.3	55.8	-7.3	48.5	-0.8	-8.1	47.8	0.9	0.3	1.1	0.0	1.2	0.0	0.0	1.2	-98.4%	n.m.	-98.0%	n.m.	-97.6%	-96.8%	n.m.	-97.6%
Changes/ Purchase of financial assets	-25.6	-12.4	-38.0	-223.9	-261.9	-15.9	-239.8	-277.8	-10.2	-14.2	-24.4	-146.1	-170.5	-97.8	-244.0	-268.3	-60.3%	14.3%	-35.9%	-34.7%	-34.9%	515.3%	1.8%	-3.4%
Disposal of financial assets	31.3	38.4	69.7	261.3	331.0	9.3	270.6	340.4	9.9	28.8	38.7	20.6	59.3	9.4	30.0	68.8	-68.4%	-24.9%	-44.4%	-92.1%	-82.1%	1.0%	-88.9%	-79.8%
Payments for investments in non-financial assets	0.0	0.0	0.0	-500.2	-500.2	0.0	-500.2	-500.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	-100.0%	-100.0%	n.m.	-100.0%	-100.0%
Disposal of non-financial non-operative assets	0.0	0.0	0.0	0.0	0.0	500.5	500.5	500.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	-100.0%	-100.0%	-100.0%
Net cash flows from investing activities	-288.1	-215.8	-503.9	-737.9	-1 241.8	-98.2	-836.1	-1 340.0	-346.3	-241.0	-587.3	-638.2	-1 225.6	-352.2	-990.4	-1 577.8	20.2%	11.7%	16.6%	-13.5%	-1.3%	258.7%	18.5%	17.0%
thereof: from discontinued operations	0.0	0.0	0.0	-6.5	-6.5	0.0	-6.5	-6.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	-100.0%	-100.0%	n.m.	-100.0%	-100.0%
Dividend payments to Merck KGaA shareholders	0.0	-168.0	-168.0	0.0	-168.0	0.0	0.0	-168.0	0.0	-180.9	-180.9	0.0	-180.9	0.0	0.0	-180.9	n.m.	7.7%	7.7%	n.m.	7.7%	n.m.	n.m.	7.7%
Dividend payments to non-controlling interests	-5.1	-0.2	-5.3	-0.4	-5.8	-0.7	-1.2	-6.5	-7.3	-0.2	-7.4	-0.4	-7.8	-0.6	-1.0	-8.4	42.2%	-27.2%	39.2%	-4.9%	35.8%	-24.9%	-17.3%	29.0%
Profit transferred to E.Merck	-57.6	-454.6	-512.2	0.0	-512.2	0.0	0.0	-512.2	-48.2	-519.1	-567.3	0.0	-567.3	0.0	0.0	-567.3	-16.3%	14.2%	10.8%	n.m.	10.8%	n.m.	n.m.	10.8%
Changes in financial liabilities to E.Merck	-34.1	389.6	355.5	-181.5	174.0	-166.6	-348.1	7.5	-25.3	471.0	445.7	-175.0	270.7	-191.9	-366.9	78.8	-25.7%	20.9%	25.4%	-3.6%	55.6%	15.2%	5.4%	>1.000%
Other changes in net equity	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.0	0.0	-0.1	-0.1	-0.1	0.0	-0.1	-0.1	n.m.	373.0%	>1.000%	340.1%	587.1%	n.m.	n.m.	n.m.
Changes in current and non-current financial liabilities	638.2	-68.9	569.3	-198.2	371.1	-1 112.7	-1 310.9	-741.6	86.5	-830.1	-743.6	-955.4	-1 699.0	-126.6	-1 082.0	-1 825.6	-86.5%	>1.000%	n.m.	382.0%	n.m.	-88.6%	-17.5%	146.2%
Other changes from financing activities	0.1	0.0	0.1	0.0	0.1	-101.5	-101.5	-101.4	0.1	-0.1	-0.1	0.0	0.0	0.0	0.1	0.0	-38.0%	>1.000%	n.m.	-10.9%	n.m.	n.m.	n.m.	n.m.
Net cash flows from financing activities	541.5	-302.1	239.4	-380.1	-140.7	-1 381.3	-1 761.4	-1 522.0	5.7	-1 059.4	-1 053.7	-1 130.8	-2 184.5	-319.1	-1 449.9	-2 503.5	-98.9%	250.6%	n.m.	197.5%	>1.000%	-76.9%	-17.7%	64.5%
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Changes in cash and cash equivalents	769.9	-15.7	754.2	52.4	806.6	-191.3	-138.9	615.3	875.4	-412.2	463.3	-302.3	160.9	373.5	71.2	534.4	13.7%	>1.000%	-38.6%	n.m.	-80.0%	n.m.	n.m.	-13.1%
Changes in cash and cash equivalents due to currency translation	-20.1	-2.7	-22.8	-16.6	-39.4	-1.1	-17.6	-40.4	6.8	-0.5	6.3	0.6	6.9	2.5	3.1	9.4	n.m.	-81.5%	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Cash and cash equivalents as of January 1st	780.6	0.0	780.6	0.0	780.6	0.0	0.0	780.6	1 355.4	0.0	1 355.4	0.0	1 355.4	0.0	0.0	1 355.4	73.6%	n.m.	73.6%	n.m.	73.6%	n.m.	n.m.	73.6%
Cash and cash equivalents	1 530.4	-18.4	1 512.0	35.9	1 547.8	-192.4	-156.5	1 355.5	2 237.7	-412.7	1 825.0	-301.7	1 523.3	376.0	74.3	1 899.3	46.2%	>1.000%	20.7%	n.m.	-1.6%	n.m.	n.m.	40.1%
Changes in cash and cash equivalents due to change in scope of consolidation	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Business Free Cash Flow	1 181.3	1 074.2	2 255.5	1 700.7	3 956.2	1 245.2	2 945.9	5 201.4	1 510.6	1 576.2	3 086.8	1 551.9	4 638.7	1 464.2	3 016.1	6 102.9	27.9%	46.7%	36.9%	-8.7%	17.3%	17.6%	2.4%	17.3%
EBITDA pre	-175.3	-220.9	-396.2	-258.4	-654.5	-784.1	-1 042.5	-1 438.7	-224.9	-267.4	-492.3	-311.6	-803.9	-565.2	-876.8	-1 369.1	28.3%	21.0%	24.3%	20.6%	22.8%	-27.9%	-15.9%	-4.8%
CAPEX on PPE and Software	-101.3	-94.0	-195.3	109.5	-85.9	133.9	243.4	48.1	-168.6	-101.5	-270.2	-196.0	-466.2	-140.6	-336.6	-606.8	66.4%	8.0%	38.3%	n.m.	443.0%	n.m.	n.m.	n.m.
Changes in trade accounts receivable	-161.5	84.8	-76																					

Balance Sheet Merck KGaA, Darmstadt, Germany Group

€ million

	2020				2021				Shares of Totals				Shares of Totals			
	31.mar	30.cze	30.wrz	31. Dez	31.mar	30.cze	30.wrz	31.gru	31.mar	30.cze	30.wrz	31. Dez	31.mar	30.cze	30.wrz	31.gru
Current assets	10 012.8	9 726.2	10 257.6	9 280.3	10 617.5	10 181.8	10 315.1	10 982.0	22.4%	22.2%	23.7%	22.2%	24.2%	23.6%	23.5%	24.2%
Cash and cash equivalents	1 530.4	1 512.0	1 547.8	1 355.4	2 237.7	1 825.0	1 523.3	1 899.3	3.4%	3.5%	3.6%	3.2%	5.1%	4.2%	3.5%	4.2%
Other current financial assets	81.0	32.0	85.1	124.7	60.3	44.8	141.7	174.0	0.2%	0.1%	0.2%	0.3%	0.1%	0.1%	0.3%	0.4%
Trade and other current receivables	3 689.8	3 508.9	3 487.3	3 220.6	3 654.1	3 656.6	3 752.5	3 646.1	8.2%	8.0%	8.1%	7.7%	8.3%	8.5%	8.6%	8.0%
Inventories	3 443.1	3 537.1	3 427.6	3 293.7	3 462.4	3 563.9	3 759.9	3 900.5	7.7%	8.1%	7.9%	7.9%	7.9%	8.3%	8.6%	8.6%
Contract assets	84.7	92.5	106.2	169.0	162.3	114.2	176.9	206.7	0.2%	0.2%	0.2%	0.4%	0.4%	0.3%	0.4%	0.5%
Other current non-financial assets	552.9	585.4	1 098.6	597.2	631.1	624.5	683.5	663.3	1.2%	1.3%	2.5%	1.4%	1.4%	1.4%	1.6%	1.5%
Current income tax receivables	630.9	458.2	504.9	519.7	409.6	352.9	277.4	492.1	1.4%	1.0%	1.2%	1.2%	0.9%	0.8%	0.6%	1.1%
Assets held for sale	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Non-current assets	34 730.4	34 095.5	32 973.3	32 516.1	33 273.0	32 963.4	33 521.3	34 380.3	77.6%	77.8%	76.3%	77.8%	75.8%	76.4%	76.5%	75.8%
Goodwill	17 375.9	17 118.0	16 511.8	15 958.8	16 540.8	16 346.8	16 669.6	17 004.5	38.8%	39.1%	38.2%	38.2%	37.7%	37.9%	38.0%	37.5%
Intangible assets other than goodwill	9 089.3	8 664.1	8 172.5	7 653.3	7 764.6	7 612.6	7 628.0	7 612.4	20.3%	19.8%	18.9%	18.3%	17.7%	17.6%	17.4%	16.8%
Property, plant and equipment	6 110.4	6 067.3	6 027.5	6 420.9	6 551.6	6 601.4	6 761.3	7 217.0	13.7%	13.8%	13.9%	15.4%	14.9%	15.3%	15.4%	15.9%
Investments at equity	0.0	0.0	2.1	2.0	2.1	2.1	2.2	2.8	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Other non-current financial assets	692.0	673.5	655.5	822.2	768.1	742.5	792.2	911.2	1.5%	1.5%	1.5%	2.0%	1.8%	1.7%	1.8%	2.0%
Other non-current receivables	21.4	20.6	25.5	25.4	27.8	28.6	28.5	25.4	0.0%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
Other non-current non-financial assets	83.2	84.4	81.4	80.8	84.7	87.4	85.0	94.8	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
Non-current income tax receivables	10.5	5.8	9.6	9.9	10.0	9.9	9.7	9.8	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Deferred tax assets	1 347.6	1 461.9	1 487.3	1 542.7	1 523.3	1 532.2	1 544.8	1 502.5	3.0%	3.3%	3.4%	3.7%	3.5%	3.6%	3.5%	3.3%
Total assets	44 743.2	43 821.7	43 230.9	41 796.4	43 890.5	43 145.2	43 836.4	45 362.3	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Current liabilities	10 764.3	10 079.8	9 709.2	9 231.4	10 652.5	9 819.6	9 793.3	10 432.2	24.1%	23.0%	22.5%	22.1%	24.3%	22.8%	22.3%	23.0%
Current financial debt	3 716.7	4 008.9	3 683.3	2 357.1	3 346.5	3 277.7	2 769.7	2 531.4	8.3%	9.1%	8.5%	5.6%	7.6%	7.6%	6.3%	5.6%
Trade and other current payables	1 807.4	1 763.7	1 683.7	1 767.6	1 936.8	2 106.7	2 131.6	2 380.2	4.0%	4.0%	3.9%	4.2%	4.4%	4.9%	4.9%	5.2%
Refund liabilities	626.1	596.8	680.2	666.0	774.6	746.5	739.4	838.9	1.4%	1.4%	1.6%	1.6%	1.8%	1.7%	1.7%	1.8%
Other current financial liabilities	1 021.4	408.5	381.9	1 007.9	950.1	392.2	372.1	1 191.8	2.3%	0.9%	0.9%	2.4%	2.2%	0.9%	0.8%	2.6%
Other current non-financial liabilities	1 225.5	1 121.8	1 302.8	1 359.6	1 503.3	1 305.2	1 499.9	1 468.3	2.7%	2.6%	3.0%	3.3%	3.4%	3.0%	3.4%	3.2%
Income tax liabilities	1 463.0	1 319.3	1 447.0	1 460.3	1 603.9	1 464.9	1 570.9	1 420.7	3.3%	3.0%	3.3%	3.5%	3.7%	3.4%	3.6%	3.1%
Current provisions	822.0	781.0	424.1	460.5	419.3	382.2	518.4	377.3	1.8%	1.8%	1.0%	1.1%	1.0%	0.9%	1.2%	0.8%
Current employee benefit provisions	82.1	79.8	106.2	152.3	117.9	144.1	191.3	223.6	0.2%	0.2%	0.2%	0.4%	0.3%	0.3%	0.4%	0.5%
Liabilities included in disposal groups classified as he	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Non-current liabilities	15 378.6	15 716.0	15 525.9	15 548.4	14 255.4	13 964.4	13 364.1	13 514.6	34.4%	35.9%	35.9%	37.2%	32.5%	32.4%	30.5%	29.8%
Non-current financial debt	10 136.6	10 080.8	9 977.5	9 785.1	9 000.8	8 720.7	8 194.9	8 269.7	22.7%	23.0%	23.1%	23.4%	20.5%	20.2%	18.7%	18.2%
Other non-current financial liabilities	44.1	53.8	58.6	62.2	62.1	67.8	79.0	105.8	0.1%	0.1%	0.1%	0.1%	0.1%	0.2%	0.2%	0.2%
Other non-current non-financial liabilities	90.1	89.0	110.1	99.9	82.8	73.6	58.6	56.5	0.2%	0.2%	0.3%	0.2%	0.2%	0.2%	0.1%	0.1%
Non-current provisions	252.3	254.6	255.8	280.5	274.7	350.9	270.1	269.3	0.6%	0.6%	0.6%	0.7%	0.6%	0.8%	0.6%	0.6%
Non-current employee benefit provisions	3 060.5	3 524.6	3 533.8	3 879.6	3 395.3	3 350.1	3 388.0	3 401.8	6.8%	8.0%	8.2%	9.3%	7.7%	7.8%	7.7%	7.5%
Deferred tax liabilities	1 795.1	1 713.2	1 590.1	1 441.0	1 439.7	1 401.2	1 373.6	1 411.4	4.0%	3.9%	3.7%	3.4%	3.3%	3.2%	3.1%	3.1%
Net equity	18 600.2	18 025.9	17 995.8	17 016.6	18 982.6	19 361.3	20 679.1	21 415.6	41.6%	41.1%	41.6%	40.7%	43.2%	44.9%	47.2%	47.2%
Equity capital	565.2	565.2	565.2	565.2	565.21	565.2	565.2	565.2	1.3%	1.3%	1.3%	1.4%	1.3%	1.3%	1.3%	1.2%
Capital reserves	3 813.7	3 813.7	3 813.7	3 813.7	3 813.7	3 813.7	3 813.7	3 813.7	8.5%	8.7%	8.8%	9.1%	8.7%	8.8%	8.7%	8.4%
Retained earnings	11 977.5	11 753.2	12 581.2	12 377.5	13 511.1	14 134.1	14 955.3	15 134.5	26.8%	26.8%	29.1%	29.6%	30.8%	32.8%	34.1%	33.4%
Gain/losses recognized immediately in equity	2 199.9	1 850.0	968.2	189.1	1 025.8	780.3	1 273.2	1 824.5	4.9%	4.2%	2.2%	0.5%	2.3%	1.8%	2.9%	4.0%
Non-controlling interest	43.9	43.8	67.4	71.1	66.7	68.1	71.8	77.8	0.1%	0.1%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
Total liabilities and stockholders' equity	44 743.2	43 821.7	43 230.9	41 796.4	43 890.5	43 145.2	43 836.4	45 362.3	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

	2020				2021				Shares of Totals				Shares of Totals			
	31.mar	30.cze	30.wrz	31. Dez	31.mar	30.cze	30.wrz	31.gru	31.mar	30.cze	30.wrz	31. Dez	31.mar	30.cze	30.wrz	31.gru
Financial debt	13 853.3	14 089.7	13 660.8	12 142.2	12 347.4	11 998.4	10 964.5	10 801.1	31.0%	32.2%	31.6%	29.1%	28.1%	27.8%	25.0%	23.8%
Net financial debt	12 285.2	12 560.2	12 082.1	10 758.2	10 080.6	10 140.7	9 320.2	8 753.0	27.5%	28.7%	27.9%	25.7%	23.0%	23.5%	21.3%	19.3%